[COMPANY_001] Research and Development  
KJX839/inclisiran 
Clinical Trial Protocol CKJX839C12302   
Two part (double-blind inclisiran versus placebo [Year 1] 
followed by [CONTACT_31463]-l abel inclisiran [Year 2]) randomized 
multicenter study to evaluate safety, tolerability, and 
efficacy of inclisiran in adolescents (12 to less than 18 
years) with homozygous familial hypercholesterolemia 
and elevated LDL-cholesterol (ORION-1 3) 
Document type:  Amended Protocol Version  
EUDRACT number:  2020 -002755 -38 
Version number:  02 (Clean ) 
Clinical Trial Phase:  III 
Release date:  17-Feb-2023 (Content Final)
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
[COMPANY_001]  Confidential  Page 2 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Table of contents  
Table of contents ................................................................................................................. [ADDRESS_683632] of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Amendment 2 (17- Feb-2023) ................................................................................................... 12 
Amendment 1 (01- Oct-2020) ................................................................................................... 14 
Protocol summary  .............................................................................................................. 16 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.2 Purpose .................................................................................................................. 20 
2 Objectives and endpoints ................................................................................................... 21 
2.1 Primary estimands  ................................................................................................. 22 
2.2 Secondary estimands ............................................................................................. 22 
3 Study design ...................................................................................................................... 22 
4 Rationale ............................................................................................................................ 24 
4.1 Rationale for study design ..................................................................................... 24 
4.1.1 Rationale for choice of background therapy ......................................... 25 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 25 
4.3 Rationale for choice of control drugs (comparator/placebo)  ................................. 26 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 26 
4.5 Risks and benefits .................................................................................................. 27 
5 Study Population ............................................................................................................... 28 
5.1 Inclusion criteria  .................................................................................................... 28 
5.2 Exclusion criteria  ................................................................................................... 28 
6 Treatment  ........................................................................................................................... 30 
6.1 Study treatment ...................................................................................................... 30 
6.1.1 Investigational and control drugs .......................................................... 30 
6.1.2 Additional study treatments .................................................................. 31 
6.1.3 Treatment arms/group  ........................................................................... 31 
6.1.4 Treatment duration  ................................................................................ 31 
6.2 Other treatment(s)  .................................................................................................. 32 
6.2.1 Concomitant therapy  ............................................................................. 32 
6.2.2 Prohibited medication  ........................................................................... 33 
6.3 Participant numbering, treatment assignment, randomization  .............................. 33 
6.3.1 Participant numbering  ........................................................................... 33 
[COMPANY_001]  Confidential  Page 3 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
6.3.2 Treatment assignment, randomization  .................................................. 34 
6.4 Treatment blinding  ................................................................................................ 34 
6.5 Dose escalation and dose modification .................................................................. 35 
6.5.1 Dose modifications ................................................................................ 35 
6.5.2 Follow-up for toxicities ......................................................................... 35 
6.6 Additional treatment guidance ............................................................................... 37 
6.6.1 Treatment compliance  ........................................................................... 37 
6.6.2 Recommended treatment of adverse events  .......................................... 38 
6.6.3 Emergency breaking of assigned treatment code  .................................. 38 
6.7 Preparation and dispensation  ................................................................................. 38 
6.7.1 Handling of study treatment and additional treatment .......................... 39 
6.7.2 Instruction for prescribing and taking study treatment ......................... 39 
7 Informed consent procedures ............................................................................................ 40 
8 Visit schedule and assessments  ......................................................................................... 41 
8.1 Screening  ............................................................................................................... 46 
8.1.1 Information to be collected on screening failures ................................. 46 
8.2 Participant demographics/other baseline characteristics  ....................................... 46 
8.3 Efficacy  .................................................................................................................. 46 
8.3.1 LDL -cholesterol  .................................................................................... 47 
8.3.2 Other efficacy biomarkers  ..................................................................... 47 
  47 
  47 
8.3.5 Appropriateness of efficacy assessments  .............................................. 47 
8.4 Safety  ..................................................................................................................... 48 
8.4.1 Laboratory evaluations .......................................................................... 48 
8.4.2 Electrocardiogram (ECG) ..................................................................... 50 
8.4.3 Pregnancy .............................................................................................. 50 
8.4.4 Other safety evaluations  ........................................................................ 51 
8.4.5 Appropriateness of safety measurements  .............................................. 52 
8.5 Additional assessments  .......................................................................................... 52 
  52 
8.5.2 Biomarkers  ............................................................................................ 52 
  52 
9 Study discontinuation and completion .............................................................................. 53 
9.1 Discontinuation and completion ............................................................................ 53 
9.1.1 Study treatment discontinuation and study discontinuation.................. 53 
9.1.2 Withdrawal of informed consent  ........................................................... 54 

[COMPANY_001]  Confidential  Page 4 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
9.1.[ADDRESS_683633]- study treatment  .......................................................... 56 
10 Safety monitoring and reporting  ........................................................................................ 56 
10.1 Definition of adverse events and reporting requirements ...................................... 56 
10.1.1 Adverse events ...................................................................................... 56 
10.1.2 Serious adverse events  .......................................................................... 58 
10.1.3 SAE reporting........................................................................................ 59 
10.1.4 Pregnancy reporting .............................................................................. 59 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 60 
10.2 Additional Safety Monitoring  ................................................................................ 60 
10.2.1 Liver safety monitoring  ......................................................................... 60 
10.2.2 Renal safety monitoring  ........................................................................ 61 
10.2.3 Other safety monitoring  ........................................................................ 61 
10.2.4 Data Monitoring Committee  ................................................................. 62 
10.2.5 Steering Committee  ............................................................................... 62 
11 Data Collection and Database management  ...................................................................... 62 
11.1 Data collection  ....................................................................................................... 62 
11.2 Database management and quality control ............................................................ 63 
11.3 Site monitoring  ...................................................................................................... 63 
12 Data analysis and statistical methods  ................................................................................ 64 
12.1 Analysis sets .......................................................................................................... 64 
12.2 Participant demographics and other baseline characteristics  ................................. 64 
12.3 Treatments  ............................................................................................................. 64 
12.4 Analysis of the primary endpoint(s)/estimand(s) .................................................. 65 
12.4.1 Definition of primary endpoint and estimand ....................................... 65 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 65 
12.4.3 Handling of remaining intercurrent events of primary estimand  .......... 65 
12.4.4 Handling of missing values not related to intercurrent event  ............... 65 
12.4.5 Sensitivity analyses for primary endpoint/estimand  ............................. 65 
12.4.6 Supplementary analysis ......................................................................... 65 
12.4.7 Supportive analyses  ............................................................................... 65 
12.5 Analysis of secondary endpoints/estimands  .......................................................... 66 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s) .................................... 66 
12.5.2 Safety endpoints .................................................................................... 66 
12.5.3 Biomarkers  ............................................................................................ 68 
  68 

[COMPANY_001]  Confidential  Page 5 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
  68 
  68 
12.7 Interim analyses  ..................................................................................................... 69 
12.8 Sample size calculation .......................................................................................... 69 
12.8.1 Primary endpoint(s)  ............................................................................... 69 
13 Ethical considerations and administrative procedures  ...................................................... 69 
13.1 Regulatory and ethical compliance ........................................................................ 69 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 69 
13.3 Publication of study protocol and results............................................................... 70 
13.4 Quality Control and Quality Assurance  ................................................................. 70 
14 Protocol adherence  ............................................................................................................ 70 
14.1 Protocol amendments ............................................................................................. 71 
15 References  ......................................................................................................................... 72 
16 Appendices ........................................................................................................................ 76 
16.1 Appendix 1: Diagnostic criteria for HoFH ............................................................ 76 
16.2 Appendix 2: Clinically notable laboratory values and vital signs ......................... 77 
16.3 Appendix 3: Liver event and laboratory trigger definitions & follow-up 
requirements .......................................................................................................... 78 
16.4 Appendix 4: Specific Renal Alert Criteria and Actions and Event Follow-up ...... 80 
16.5 Appendix 5: Recommended Neurological Examination ....................................... 83 
16.6 Appendix 6: Sampson Criteria for Diagnosing Anaphylaxis ................................ 87 
16.7 Appendix 7: Reference table blood volume by [CONTACT_8497] ......................................... [ADDRESS_683634] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 21 
Table 6 -1 Investigational and control drug ............................................................ 31 
Table 6 -2 Prohibited medication  ........................................................................... 33 
Table 6 -3 Guidance on specific clinical and diagnostic assessments which 
can be performed to rule out possible alternative causes of observed LFT abnormalities ................................................................. 36
 
Table 8 -1 Assessment Schedule  ............................................................................ 42 
Table 8 -2 Assessments &  Specifications ............................................................... 48 
Table 8 -3 Laboratory Assessments  ........................................................................ 49 
Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 60
 
Table 16-1 Criteria for clinically notable vital signs  ............................................... 77 
Table 16-2 Clinically notable laboratory abnormalities for selected tests  .............. 77 
Table 16-3 Liver event and laboratory trigger definitions  ...................................... 78 

[COMPANY_001]  Confidential  Page 6 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Table 16-4 Follow up requirements for liver laboratory triggers with liver 
symptoms .............................................................................................. 78 
Table 16-5 Follow up requirements for liver laboratory triggers  ............................ 79 
Table 16-6 Specific Renal Alert Criteria and Actions  ............................................. 81 
Table 16-7 Renal event follow -up ........................................................................... 82 
Table 16-8 Grade Strength  ...................................................................................... 83 
Table 16-9 Reflex responses  .................................................................................... 85 
Table 16-10 Reference table – blood collection volumes by [CONTACT_18694] ............... [ADDRESS_683635] of figures  
Figure 3-1 Study Design ......................................................................................... 24 
 
[COMPANY_001]  Confidential  Page 7 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
List of abbreviations  
ADA Anti-drug antibodies  
ADR  Adverse Drug Reaction  
AE(s)  Adverse event(s)  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase  
Apo A1  Apolipoprotein A1  
Apo B  Apolipoprotein B  
ASCVD  Atherosclerotic cardiovascular disease  
AST Aspartate aminotransferase  
ATC Anatomical Therapeutic Chemical  
BfArM  Federal Institute for Drugs and Medical Devices  
BMI Body Mass Index  
BUN  Blood urea nitrogen  
C(P)K  Creatine (phospho)kinase  
CFR Code of Federal Regulation  
CHD  Coronary heart disease  
  
CMO&PS  Chief Medical Office and Patient Safety  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract Research Organization  
CTFG  Clinical Trials Facilitation and Coordination Group  
CTT Clinical trial team  
CV Cardiovascular  
CVD  Cardiovascular disease  
DBP Diastolic Blood Pressure  
DILI Drug induced liver injury  
DIN Drug -induced nephrotoxicity  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
eGFR  Estimated glomerular filtration rate  
EOS  End of study  
ERCP  Endoscopic retrograde cholangiopancreatography  
EudraCT  European Union Drug Regulating Authorities Clinical Trials  
FAS Full Analysis Set  
FH Familial Hypercholesterolemia  
FPG Fasting plasma glucose  
GalNAc  N-Acteylgalactosamine  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transferase  
GLDH  Glutamate dehydrogenase  
HbA1c  Hemoglobin A1c  
HDL-C High density lipoprotein cholesterol  

[COMPANY_001]  Confidential  Page 8 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
HeFH  Heterozygous Familial Hypercholesterolemia   
HoFH  Homozygous Familial Hypercholesterolemia  
  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for 
Human Use)  
IEC Independent Ethics Committee  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ISR(s)  Injection site reaction(s)  
IUD Intrauterine device  
IUS Intrauterine system  
kg Kilogram(s)  
LDL Low density lipoprotein  
LDL-C Low density lipoprotein cholesterol  
LDLR  Low density lipoprotein receptor  
   
LFT(s)  Liver function test(s)  
LLOQ  Lower limit of quantification  
Lp(a)  Lipoprotein (a)  
MCV  Mean corpuscular volume  
mg milligram(s)  
MI Myocardial infarction  
mL milliliter(s)  
MMRM  Mixed -effect model for repeated measures  
MRI Magnetic resonance imaging  
mRNA(s)  Messenger ribonucleic acid(s)  
PCR  Protein -creatinine ratio  
PCSK9  Proprotein convertase subtilisin/kexin type 9  
PD Pharmacodynamic(s)  
PEF Peak expi[INVESTIGATOR_156296](s)  
PT/INR  Prothrombin Time / International Normalized Ratio  
RBC  Red blood cell(s)  
RISC(s)  Ribonucleic acid (RNA) -induced silencing complex(es)  
RNA  Ribonucleic acid  
s.c. Subcutaneous  
SAE Serious adverse event  
SAP Statistical Analysis Plan  
SBP Systolic Blood Pressure  
SC Steering Committee  
sCr Serum creatinine  
SD Standard deviation  
siRNA(s)  Small interfering ribonucleic acid(s)  

[COMPANY_001]  Confidential  Page 9 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
SoC Standard of Care  
SOP(s)  Standard Operating Procedure(s)  
S[LOCATION_003]R(s)  Suspected Unexpected Serious Adverse Reaction(s)  
TBV Total blood volume  
TEAE  Treatment emergent adverse event  
TSH Thyroid stimulating hormone  
ULN Upper limit of normal  
VLDL -C Very low density  lipoprotein cholesterol  
WBC  White blood cell(s)  
[COMPANY_001]  Confidential  Page 10 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Glossary of terms  
Additional 
treatment  Medicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product (e.g. any background therapy)  
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), saliva, tissue, urine, 
stool, etc. taken from a study participant  
Cohort  A specific group of participants fulfilling certain criteria  
Control drug  Any study drug (an active drug or an inactive drug, such as a placebo) which is used as a 
comparator to reduce assessment bias, preserve blinding of investigational drug, assess 
internal validity, and/or evaluate comparative effects of the investigational drug 
Dosage  Dose of the study treatment given to the participant in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study data using 
data collection systems, such as Web-based applications, interactive voice response systems and clinical laboratory interfaces. EDC includes the use of Electronic Case 
Report Forms (eCRFs) which are used to capture data transcribed from paper source 
forms used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant or at a later 
point in time as defined by [CONTACT_30761]/time of participant entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol).  
Estimand  A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_301987]. It summarizes at a population-level what the outcomes would be in the same patients under different treatment conditions being compared. Attributes  of an 
estimand include the population, variable (or endpoint) and treatment of interest, as well as the specification of how the remaining intercurrent events are addressed and a 
population -level summary for the variable.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or the 
existence  of the measurements associated with the clinical question of interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study.  
Medication 
number  A unique identifier on the label of each study drug package in studies that dispense study 
drug using an IRT system.  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for randomization and who 
did not take study treatment, but have been inadvertently randomized into the study  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. concomitant 
or rescue therapy)  
Part  A sub -division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple dose part, or a part in participants with established disease and in those with newly -diagnosed 
disease  
Participant  A trial participant (can be a healthy volunteer or a patient)  
Participant number  A unique number assigned to each participant upon signing the informed consent. This number is the definitive, unique identifier for the participant and should be used to identify 
the participant throughout the study for all data collected, sample labels, etc. 
Period A minor subdivision of the study timeline; divides phases into smaller functional segments 
such as screening, baseline, titration, washout, etc.  
Personal data  Participant information collected by [CONTACT_6554]. This data includes participant identifier 
information, study information and biological samples.  
Premature participant 
withdrawal  Point/time when the participant exits from the study prior to the planned completion of all study drug administration and/or assessments; at this time all study drug administration is 
discontinued and no further assessments are planned  
[COMPANY_001]  Confidential  Page 11 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Randomization 
number  A unique identifier assigned to each randomized participant  
Screen Failure  A participant who did not meet one or more criteria that were required for participation in 
the study  
Source 
Data/Document  Source data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a spreadsheet or even hard-
coded data, such as paper or eSource  
Start of the clinical 
trial The start of the clinical trial is defined as the signature [CONTACT_6671] [CONTACT_301988]; 
includes investigational drug(s), control(s) or background therapy  
Study treatment 
discontinuation  When the participant permanently stops taking any of the study drug(s) prior to the 
defined study treatment completion date (if any) for any reason; may or may not also be 
the point/time of study discontinuation  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and may 
consist of [ADDRESS_683636], which 
might or might not be the same as the study treatment.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address 
the clinical question.  The specification of the variable might include whether the 
participant experiences an intercurrent event.  
Withdrawal of 
study consent  Withdrawal of consent from the study occurs only when a participant does not want to 
participate in the study any longer and does not allow any further collection of personal 
data  
[COMPANY_001]  Confidential  Page 16 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Protocol summary  
Protocol 
number  CKJX839C12302  
Full Title  Two part (double-blind inclisiran versus placebo [Year 1] followed by [CONTACT_31463]- label inclisiran  
[Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of 
inclisiran in adolescents (12 to less than 18 years) with homozygous familial 
hypercholesterolemia and elevated LDL -cholesterol (ORION -13) 
Brief title  A multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in adolescents 
(12 to less than 18 years) with homozygous familial hypercholesterolemia   
Sponsor and 
Clinical Phase  [COMPANY_001] / Phase III 
Investigation 
type Drug  
Study type  Interventional  
Purpose and 
rationale This is a pi[INVESTIGATOR_301964], tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C). The use of inclisiran for the treatment 
of HoFH in adolescent patients who require additional lipid lowering will be investigated in 
order to obtain needed pediatric information on inclisiran.  
Primary Objective(s)  The primary objective of the study is to evaluate the effect of inclisiran compared to placebo 
on reducing LDL-C [percent change] at Day 330 (Year 1) in adolescents (aged 12 to <18 
years) with HoFH and elevated LDL -C 
Secondary Objectives Evaluate the effect of inclisiran compared to placebo on reducing LDL- C [time-adjusted 
percent change] over Year [ADDRESS_683637] of inclisiran compared to placebo (for Year 1) and long-term (up to Day 
720), on lowering LDL-C, other lipoprotein and lipid parameters, and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) over time  
Evaluate the safety and tolerability of inclisiran compared to placebo (for Year 1) and long-
term (up to Day 720), in adolescents (aged 12 to <18 years) with HoFH  
Study design  Two part (double-blind inclisiran versus placebo [Year 1] followed by [CONTACT_31463]- label inclisiran 
[Year 2]) randomized multicenter study   
Study 
population  Adolescents (age 12 to <18 years) with HoFH; approximately 12 participants; males and 
females  
Key Inclusion 
criteria  • HoFH diagnosed by [CONTACT_526899]  
• Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening  
• On maximally tolerated dose of statin (investigator’s discretion) with or without other 
lipid-lowering therapy (e.g. ezetimibe). Maximum tolerated dose of statin is defined as 
the maximum dose of statin that, at the investigator’s discretion, can be taken on a 
regular basis without adverse events that would lead to a reduction in statin dose  
• Participants on lipid- lowering therapi[INVESTIGATOR_014] (such as statin and/or e.g. ezetimibe) should be 
on a stable dose for ≥ 30 days before screening with no planned medication or dose 
changes during study participation  
• Participants on a documented regimen of LDL-apheresis will be allowed to continue the 
apheresis during the study, if needed. The apheresis schedule is not allowed to change 
during the double- blind period of the trial and must permit that an apheresis coinc ides 
with each study visit  
• Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 at screening  
Key Exclusion criteria  • Documented evidence of a null (negative) mutation in both LDLR alleles  
• Previous treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9  
• History of poor response to therapy with any monoclonal antibody directed towards 
PCSK9  
[COMPANY_001]  Confidential  Page 18 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
1 Introduction  
1.1 Background 
Despi[INVESTIGATOR_76572], cardiovascular disease (CVD) is the leading cause of death 
worldwide, resulting in over 17 million deaths annually ( WHO  2017). Eighty percent of all 
CVD deaths are due to coronary heart disease (CHD) or strokes. Elevated low density 
lipoprotein cholesterol (LDL -C) is a major risk factor for the development of CVD 
(Grundy et  al 2004, Go et al 2014 ). Lowering LDL -C has been shown to reduce the risk of 
death or heart attack and within the range of effects achieved so far, the clinical risk reduction is linearly proportional to the absolute LDL -C reduction ( Baigent et al 2005, 
Giugliano et  al 2017).  
Millions of people worldwide are treated with lipid -lowering therapi[INVESTIGATOR_014], predominantly statins, 
to reduce LDL -C and the associated risk of death, nonfatal myocardial infarction (MI) and 
nonfatal stroke or associated events ( Casula et  al 2012). Despi[INVESTIGATOR_301965] -lowering medications, with current therapi[INVESTIGATOR_301966] -C, many at -risk patients do not reach LDL -C goals 
(Jones et  al 2012, Jameson  et al 2014, Barkas  et al 2015, Fitzgerald  et al 2017 ). This is 
particularly true in patients with pre -existing CHD and/or diabetes or a history of familial 
hypercholesterolemia (FH), who are at the highest risk and require the most intensive management ( Davidson et  al 2005 ). 
FH is a genetic disorder that causes high levels of LDL -C in the blood and is characterized by 
[CONTACT_301990] (CV) disease. It is caused by [CONTACT_301991] (LDLR) -mediated clear ance of LDL -C, 
including (in decreasing order of prevalence) LDLR, apolipoprotein B (Apo B), and proprotein convertase subtilisin/kexin type 9 (PCSK9) ( Santos et  al 2016). There are two clinical 
manifestations depending on the presence of one or two affected alleles in these genes. The milder heterozygous form (heterozygous familial hypercholesterolemia [HeFH]) results from a single affected allele. The more severe homozy gous form (homozygous familial 
hypercholesterolemia [HoFH]) results from biallelic pathogenic variants in one of these genes, or one pathogenic variant in each of two different genes ( Santos et  al 2016 ). 
Recent studies suggest that FH is more common than previously projected, with 1/160,[ADDRESS_683638] HoFH and 1/200 to 1 in 250 people (instead of the historical 1/500) to have HeFH ( Najam  and Ray 2015, Wiegman  et al 2015 ). There are an estimated 34 million 
people with FH worldwide, but the majority remain undiagnosed (~90%) and current treatment is often suboptimal ( Wilemon  et al 2020).  
Patients with HoFH have an extremely high risk of CVD. They often have LDL -C levels 
ranging between 3- to 6 -fold higher than normal (> 13 mmol/L (500 mg/dL)) 
(Nordestgaard et  al 2013 , Wiegman  et al 2015 ), and, if untreated, many will manifest coronary 
or other CV disease in childhood or adolescence ( Wiegman  et al 2015 ). The severity of the 
HoFH phenotype depends on the residual LDLR activity; HoFH patients who are LDLR -
negative (<2% activity) have higher LDL -C levels and poorer clinical prognosis, and also tend 
to present earlier than LDLR -defective patients (2 -25% res idual activity) (Bertolini et al 2013, 
Kolansky et  al 2008, Moorjani et  al 1993, Varghese 2014). Children with HoFH primarily 
present with dermatological manifestations such as tendon xanthomas and interdigital 
[COMPANY_001]  Confidential  Page 19 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
xanthomas. Ocular manifestations include xanthelasma and corneal arcus ( Varghese 2014). 
Most individuals with HoFH experience severe atherosclerotic vascular disease by [CONTACT_526900] ( Youngblom et  al 2016).  
As the degree and duration of exposure to elevated LDL -C levels increases the atherosclerotic 
burden, early treatment of FH to lower LDL -C levels is vital (Varghese 2014) and lipid -
lowering therapy is therefore recommended to be started as early as possible in HoFH (Cuchel et  al 2014). In accordance with recommendations from the Expert Panel on Integrated 
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, a LDL -
C target of ≤130 mg/dL is recommended in children/adolescents ( Expert Panel  2011). Lifestyle 
intervention and maximal statin therapy are the mainstays of treatment in HoFH, often in combination with ezetimibe and other lipid -modifying therapy (Cuchel et  al 2014, 
Wiegman  et al 2015). Even at the highest doses of the most efficacious statins, however, only 
modest reductions in LDL -C plasma levels of 10 -25% are observed in most patients with HoFH. 
Where available, low density lipoprotein (LDL) -apheresis is regarded an important adjunctive 
treatment for HoFH, however, it is recognized that its use, including the age for initiation and frequency of treatment, represent a compromise between access to centers, the severity of the disease, affordability, and the patient’s choice ( Cuchel et  al 2014).  
Despi[INVESTIGATOR_103281], current treatment options are still limited for children with HoFH, and the known limitations of contemporary therapi[INVESTIGATOR_301968], and thus require the most intensive and aggressive management of hypercholesterolemia ( Stone et  al 2014). Thus, there remains a clear 
unmet medical need for treatments that will lower LDL -C, especially in pediatric populations.  
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the serine protease family, 
plays a key role in controlling the levels of LDLRs on the surface of hepatocytes 
(Khvorova 2017). PCSK9 is expressed and secreted into the bloodstream predominantly by [CONTACT_301992], binds LDLR both intracellularly and extracellularly and promotes the lysosomal degradation of these receptors in hepatocytes, ( Lakoski et  al 2009, Mousavi et  al 2009 ) thereby 
[CONTACT_76609] -C levels.  
Recently developed and approved PCSK9-blocking monoclonal antibodies reduce PCSK9 and lower LDL -C levels, and were also shown to significantly reduce the risk of CV events 
(Sabatine et  al 2017, Schwartz et  al 2018).  
Small interfering ribonucleic acids (siRNAs) selectively and catalytically silence the translation of their complimentary target messenger ribonucleic acids (mRNAs) in a sequence specific manner through the formation of effector ribonucleic acid (RNA)-induced silencing complexes (RISCs), utilizing a highly specific endogenous mechanism for regulating gene expression (Ray et al 2019). Inclisiran is a chemically modified double -stranded small interfering RNA, 
conjugated on the sense strand with triantennary N -Acetylgalactosamine (GalNAc) to facilitate 
uptake by [CONTACT_6566]. In hepatocytes, the antisense strand is incorporated in the R ISC and 
directs catalytic breakdown of mRNA for PCSK9. This inhibits translation of PCSK9 protein. Reduced intrahepatic PCSK9 increases LDLR recycling and expression on the hepatocyte cell surface, thereby [CONTACT_301993] -C uptake and lowering LDL -C levels in the circulation 
(Fitzgerald  et al 2017 ). 
[COMPANY_001]  Confidential  Page 20 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
In the ORION clinical development program, 3660 participants with atherosclerotic CV disease 
(ASCVD), ASCVD risk equivalent, and/or HeFH were studied in three confirmatory 18 -months 
phase III studies comparing inclisiran versus placebo adjunctive to maxima lly tolerated statin 
therapy, and an additional 681 participants were treated in phase I and phase II studies. In the phase III studies, treatment with inclisiran sodium 300 mg given by [CONTACT_6567] (s.c.) injection on Day 1, Day 90, and every 6 months the reafter, resulted in placebo -adjusted 
percentage reductions in LDL -C from baseline at Day 510 of 48% to 52%, with time -adjusted 
average reductions of 44% to 54% sustained over 18 months ( Raal et al 2020, Ray et al 2020). 
The efficacy of inclisiran was consistent across phase I, phase II and phase III studies, with no differences across a broad range of subpopulations. 
There were no clinically relevant differences in the safety profile of inclisiran compared with 
placebo, except for a higher incidence of treatment -emergent adverse events (TEAEs) at the 
injection site with inclisiran. However, all TEAEs at the injection s ite were localized, 
predominantly mild, transient, and resolved without sequelae. Inclisiran is not associated with an increased risk for hepatic or renal dysfunction, hypersensitivity, neurologic events and neurocognitive disorders, or ophthalmological events and there was no difference from placebo in new onset or worsening of diabetes. The potential for immunogenicity of inclisiran is low. Additional details on the efficacy and safety of inclisiran are available in the Investigator's Brochure (IB). 
Based on the established benefit -risk profile in adults, inclisiran  may improve the treatment of 
children/adolescents with HoFH, with a low injection burden given the only twice yearly 
dosing. 
Study CKJX839C12302 (ORION -13) is planned to investigate inclisiran in adolescents aged 
12 to <18 years of age with HoFH. 
1.2 Purpose 
Study CKJX839C12302 (ORION -13) is a pi[INVESTIGATOR_301964], 
tolerability, and efficacy of inclisiran in adolescents (aged 12 to <18 years) with HoFH and 
LDL -C >130 mg/dL (3.4 mmol/L). The use of inclisiran (as an adjunct to sta ble, optimal 
background lipid- lowering therapy) for the treatment of HoFH in adolescent patients who 
require additional lipid -lowering will be investigated in order to obtain needed pediatric 
information on inclisiran. The follow -up period (Part 2/Year 2) serves to collect longer -term 
data on inclisiran and also allows access of study participants to a potentially effective treatment.  
[COMPANY_001]  Confidential  Page 21 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• The primary objective is to evaluate the 
effect of inclisiran compared to placebo 
on reducing LDL-C [percent change] at 
Day 330 (Year 1) in adolescents (aged 12 
to <18 years) with HoFH and elevated 
LDL-C • Percentage change in LDL-C from baseline to Day 330 
(Year 1)  
See Section 2.1 for primary estimand  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• Evaluate the effect of inclisiran compared 
to placebo on reducing LDL- C [time -
adjusted percent change] over Year 1  • Time -adjusted percent change in LDL-C from baseline after 
Day 90 and up to Day 330 (Year 1)  
• Evaluate the effect of inclisiran compared 
to placebo (for Year 1) and long-term (up 
to Day 720), on lowering LDL -C, other 
lipoprotein and lipid parameters, and PCSK9 over time  • Percent change and absolute change in LDL -C, Apo B, 
lipoprotein (a) [Lp(a)], non- high density lipoprotein 
cholesterol (non-HDL -C), total cholesterol, triglycerides, 
high density lipoprotein cholesterol (HDL- C), very low 
density lipoprotein cholesterol (VLD L-C), apolipoprotein A1 
(Apo A1) and PCSK9 from baseline to each assessment 
time up to Day 720 (Year 2)  
• Evaluate the safety and tolerability of 
inclisiran compared to placebo (for Year 1) and long-term (up to Day 720), in 
adolescents (aged 12 to <18 years) with HoFH  • Incidence, severity and relationship to study drug of 
treatment -emergent adverse events (AEs) and serious 
adverse events (SAEs); vital signs; laboratory parameters; 
anti-drug antibodies (ADA) measurement; growth (height, 
weight, body mass index (BMI)); pubertal development 
(steroid hormones and Tanner staging)  

[COMPANY_001]  Confidential  Page 22 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
2.[ADDRESS_683639] is: What is the effect of the test treatment versus 
placebo on change in LDL -C after [ADDRESS_683640] of care (SoC) lipid -lowering therapy, regardle ss of treatment 
discontinuation for any reason and regardless of unforeseen change in the concomitant lipid -
lowering therapy.  
The justification for the primary estimand is that it will capture both the effect of the study drug and the effect of changes in additional medication(s) used for HoFH, if they occur, as would be the case in clinical practice.  
The primary estimand is described by [CONTACT_6570]:  
1. Population: Adolescents with the HoFH condition of interest and elevated LDL-C on 
stable optimal SoC lipid -lowering therapy. Further details about the population are 
provided in Section  5. 
2. Endpoint: Percentage change in LDL- C from baseline to Day 330 (Year 1).  
3. Treatment of interest: The randomized treatment (the investigational treatment inclisiran or the control treatment placebo) as add -on to optimal SoC lipid -lowering therapy for 
HoFH. The type and dose of the concomitant lipid -lowering therapy for HoFH must 
remain stable during Part 1 (Year 1) of the study. Further details about the investigational treatment and control treatment are provided in  Section  6. 
The summary measure: difference between treatments in mean percentage change at Day 330.  
2.2 Secondary estimands  
Not applicable. 
3 Study design  
This study is a two -part (double -blind, placebo- controlled / open -label) multicenter study in 
adolescents (aged 12 to <18 years) with HoFH and elevated LDL -C (>130 mg/dL / 3.4 mmol/L) 
on stable, individualized, optimal SoC background lipid- lowering therapy  (including 
maximally tolerated statin treatment).  
The overall study duration is 748 days (excluding a safety follow -up call 30 days after the end 
of study (EOS) visit).  
Following an approximately 4 weeks screening/run- in period, the study has two sequential parts 
(Figure 3-1).  
• Part 1 (Year 1): 12 months double-blind, parallel group period in which participants will be randomized to receive either inclisiran sodium 300 mg (equivalent to 284 mg inclisiran
*) s.c. or placebo (given at Days 1, 90 and 270). 
• Part 2 (Year 2): 12 months single arm, open- label follow -up period with all participants 
receiving inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) s.c. Participants 
randomized to placebo in Part 1 will receive inclisiran starting on Day 360 (“Switch” Day 360). Participants randomized to inclisiran in Part 1 will receive placebo on Day 360. This dose of inclisiran/placebo on Day 360 will remain blinde d in order to maintain the blind 
[COMPANY_001]  Confidential  Page 23 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
for Part 1 of the study. All participants will receive subsequent doses of open- label 
inclisiran on Days 450 and 630. 
* Inclisiran is also referred to as KJX839.  
Informed consent will be obtained before initiation of any study- specific procedures (see 
Section  5.1 and Section  7 for details). Participants who meet the inclusion/exclusion criteria 
will be required to maintain their current lipid -lowering treatment unchanged for Part 1 (Year 
1) of the study (including the screening/run -in period). Investigators must ensure that each 
participant receives individualized, optimal SoC lipid -modifying treatment [including 
maximally tolerated statin treatment (investigator’s discretion) with or without other lipid -
lowering therapy (e.g. ezetimibe)], and that this treatment was stable for ≥ 30 days before 
screening. Maximum tolerated dose of statin is defined as the maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose. Intolerance to statin must be documented. 
Approximately 12 participants who meet the inclusion/exclusion criteria will be randomized in 
a 2:1 ratio to receive either inclisiran sodium 300 mg s.c. or placebo on Day 1 (baseline). A second and third dose of inclisiran or placebo will be given on Day 90 and Day 270, respectively. The primary endpoint will be measured at Day 330. 
Participants initially randomized to placebo will transition to inclisiran starting on Day 360 and 
the study will then change to an open- label, single arm follow -up period of inclisiran sodium 
300 mg s.c. (Part 2). In order to maintain the blind for Part 1  of the study, on the “switch” day 
(Day 360), participants randomized to placebo in Part [ADDRESS_683641] injection on Day 1 and Day 360 (i.e. first dosing of inclisiran) and for at least [ADDRESS_683642] injection for all other 
dosing visits before being discharged. 
Participants on a documented regimen of LDL -apheresis will be allowed to continue their same 
regimen during the study, if needed. The apheresis schedule is not allowed to change during 
Part 1 (Year 1) of the study (including the screening/run -in period). T he apheresis schedule 
must also allow that an apheresis coincides with each study visit. Study drug is to be administered the same day, after completion of apheresis (the next scheduled apheresis should not occur within 72 hours after an administration of study drug). Blood samples for LDL -C (and 
other laboratory assessments of efficacy and safety) must be obtained immediately before the scheduled apheresis treatment at each applicable study visit (including screening and baseline (Day 1)).  
[COMPANY_001]  Confidential  Page 24 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Figure 3-1 Study Design 
  
* Primary endpoint assessed at Day 330.  # "Switch Day": Participants randomized to placebo in Part 1 
will start to receive inclisiran on Day 360. Participants randomized to inclisiran in Part 1 will receive 
placebo on Day 360 only to maintain the blind for Part 1.  
4 Rationale  
4.1 Rationale for study design  
Part 1 of the study (Year 1) has a randomized, parallel group, placebo- controlled design to 
provide evidence for the efficacy, safety, and tolerability of inclisiran in adolescents with HoFH. 
This study design is the most appropriate trial design to answer the clinical questions of interest 
on the use of inclisiran in this pediatric patient population.  
The open- label single -arm design for Part 2 of the study (Year 2) is appropriate to obtain 
additional long- term data, with a maximum number of participants exposed to the 
investigational drug. 
A screening/run- in period of approximately 4 weeks is used to ensure the entry criteria are met 
(allowing test results to be received) and to ensure stabilization of individualized, optimal SoC 
background lipid -lowering therapy prior to randomization. 
An unequal 2:1 randomization was chosen in agreement with regulatory authorities. This unequal randomization allows to maximize exposure to the active investigational drug and to enhance collection of corresponding efficacy/safety information in the pediat ric study 
population. 

[COMPANY_001]  Confidential  Page 25 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
4.1.[ADDRESS_683643] remain unchanged for Part 1 (Year 1) of the study 
(including the screening/run- in period). Optimal SoC for adolescents with HoFH comprises 
maximally tolerated statin treatment with or without additional lipid -lowering treatment (e.g. 
ezetimibe), in accordance with international/local practice and treatment guidelines as well as regulatory authorities. No specific background medication is required during the conduct of the study; any statin and other lipid -lowering therapi[INVESTIGATOR_301969] (unless specifically prohibited per protocol; see Section  5.2 and Section  6.2.2 for details). 
LDL -apheresis is also allowed as adjunctive treatment per protocol in line with current practice 
and guidelines. 
4.2 Rationale for dose/regimen and duration of treatment  
The established dose regimen for inclisiran for adults is 300 mg s.c. on Day 1, Day 90 and every 6 months thereafter. Based on nonclinical and clinical data, including phase I, II and III clinical studies as well as pharmacodynamic (PD) modeling in adult participants, the same dose and dose regimen will also be used in the present study in adolescents. 
In adult participants, maximum reductions in LDL -C and PCSK9 levels with inclisiran were 
achieved with single s.c. doses of 300 mg inclisiran sodium, with no additional meaningful 
benefit observed at higher doses. Three large pi[INVESTIGATOR_301970], ASCVD risk equivalents, and/or HeFH demonstrated that the dose regimen used in the present study (300 mg inclisiran sodium s.c. on Day 1, Day 90 and every 6 months thereafter) resulted in placebo -adjusted percentage reductions  in LDL -C from baseline at Day 
510 of 48% to 52%, with time -adjusted average reductions of 44% to 54% sustained over 18 
months. This dose and regimen also showed good tolerability of inclisiran, with a safety profile similar to placebo, except for a higher incidence of AEs at the injection site with inclisiran. No patient populations were identified that required an inclisiran dose adjustment. Doses up to 900 mg (3 -fold therapeutic dose) were studied which was safe and well tolerated in healthy adult 
subjec ts. 
Adult data has shown that the plasma PK of inclisiran does not predict PD effects. Inclisiran is rapi[INVESTIGATOR_301971] [ADDRESS_683644] processes involved between s.c. administration of inclisiran and reduction of LDL -C in the bloodstream. Additionally, after multiple administrations in the 
phase I  study, inclisiran plasma exposure ratios were close to one, indicating no PK 
accumulation. A modelling and simulation analysis based on phase II study (ORION -1) data in 
adults suggest that the PD effect of inclisiran neither strengthens nor attenuates over time after repeated administrations up to 2 years of treatment.  
[COMPANY_001]  Confidential  Page 28 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
5 Study Population  
The study population consists of adolescents (12 to <18 years) with a genetic diagnosis of HoFH  
and LDL-C >130 mg/dL (3.4 mmol/L) on optimal SoC lipid- lowering therapy.  
Approximately [ADDRESS_683645] meet all of the following criteria:  
1. Written informed consent must be obtained from the participant’s parent(s)/legal 
representative(s) prior to the adolescent’s participation in the study. A consent or assent 
may also be required for some participants depending on their age and local requirements. An informed consent must be obtained from participants once they reach the local legal age of adulthood during the study.  
2. Male or female participants, ≥12 to <18 years of age at screening 
3. HoFH diagnosed by [CONTACT_526899]; see Section  16.1 (Appendix 1) for details  
• Note: Participants with known null (negative) mutations in both LDLR alleles are 
not eligible ( see Section 5.2 exclusion criteria  #1) 
4. Fasting LDL- C >130 mg/dL (3.4 mmol/L) at the screening visit, measured at the central 
laboratory  
5. On maximally tolerated dose of statin (investigator’s discretion) with or without other lipid-lowering therapy (e.g. ezetimibe). Maximum tolerated dose of statin is defined as the 
maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose  
6. Participants on lipid -lowering therapi[INVESTIGATOR_014] (such as statin and/or e.g. ezetimibe) should be on 
a stable dose for ≥ [ADDRESS_683646] permit that an apheresis coinc ides 
with each study visit 
8. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m
2 at screening   
9. Willing to follow all study procedures including adherence to study visits, fasting blood 
draws, and compliance with study treatment regimens 
5.2 Exclusion criteria 
Participants meeting any of the following criteria are not eligible for inclusion in this study.  
1. Documented evidence of a null (negative)  mutation in both LDLR alleles 
2. Previous treatment (within 90 days of screening) with monoclonal antibodies directed 
towards PCSK9  
3. History of poor response to therapy with any monoclonal antibody directed towards 
PCSK9 (e.g. <15% reduction in LDL- C) 
4. Treatment with mipomersen or lomitapi[INVESTIGATOR_5328] (within 5 months of screening) 
[COMPANY_001]  Confidential  Page 29 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
5. (i) Active liver disease defined as any known current infectious, neoplastic, or metabolic 
pathology of the liver or (ii) unexplained alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x ULN (except patients with Gilb ert’s syndrome) at screening confirmed by a repeat measurement at least 
1 week apart  
6. Females who are pregnant or nursing, or who are of child-bearing potential, defined as all women physiologically capable of becoming pregnant (e.g. are menarchal) unless  they 
agree to abstinence or, if sexually active, agree to the use of effective methods of contraception during dosing of study treatment. Female participants of child-bearing potential, who are or might become sexually active, must be informed of the need to prevent pregnancy during the study. The effective contraception methods are: 
• Barrier method: Condom or Occlusive cap (e.g. diaphragm or cervical/vault caps). For [LOCATION_006] sites only (if applicable): with spermicidal foam/gel/film/cream/ vaginal suppository 
• Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception 
• The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen 
• If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF)  
• Adolescent females who have not reached menarche are exempt from the above requirements; however, to be eligible for inclusion in the study, they must be willing to comply with the above requirements if they gain child-bearing potential during the study 
7. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the participant at significant risk (according to investigator's [or delegate's] judgment) if he/she p articipates in the 
clinical study  
8. An underlying known disease, or surgical, physical, or medical condition that, in the 
opi[INVESTIGATOR_871] (or delegate) might interfere with interpretation of the clinical 
study results  
9. Heterozygous FH 
10. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to: 
• Participants who are unable to communicate or to cooperate with the investigator  
• Unlikely to comply with the protocol requirements, instructions, and study- related 
restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study) 
• Have any medical or surgical condition, which in the opi[INVESTIGATOR_526894] 30 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
• Persons directly involved in the conduct of the study 
11. Treatment with other investigational medicinal products or devices within 30 days or five 
half-lives, whichever is longer 
12. Planned use of other investigational products or devices during the course of the study 
13. Hypersensitivity to any of the ingredients of inclisiran  
14. Known history of alcohol and/or drug abuse 
15. Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome 
16. Major adverse cardiovascular events within 1 month prior to randomization  
17. Severe concomitant non- cardiovascular disease that carries the risk of reducing life 
expectancy to less than 2 years  
18. History of malignancy that required surgery (excluding local and wide- local excision), 
radiation therapy and/or systemic therapy during the 3 years prior to randomization  
19. Poorly controlled diabetes mellitus (i.e. hemoglobin A1c (HbA 1c) >10.0 %) 
20. Previous participation in this study 
6 Treatment 
6.1 Study treatment  
Participants will be randomized 2:1 to double -blind s.c. injections of inclisiran sodium 300 mg 
or placebo in Part 1 (Year 1) of the study, and subsequently all participants will receive open -
label s.c. injections of inclisiran sodium 300 mg in Part 2 (Year 2) of the study. 
Investigational and control drugs will not be dispensed to the participants but administered by 
[CONTACT_301999]. 
6.1.1 Investigational and control drugs 
The sponsor will provide the following investigational and control drugs as single -use pre -filled 
syringes for s.c. injection ( Table  6-1).  
Part 1 (Year 1) including “Switch” Day 360:  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution 
• Placebo formulation to this active drug formulation  
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection). 
Placebo will be administered as a 1.5 mL s.c. injection to match the dose in the inclisiran arm.  
The placebo pre -filled syringes will be blinded and look identical to the corresponding inclisiran 
pre-filled syringes.  
Part 2 (Year 2):  
• Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution 
[COMPANY_001]  Confidential  Page 31 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Table 6-1 Investigational and control drug  
Investigational/ Control 
Drug  Pharmaceutical 
Dosage Form  Route of 
Administration  Supply Type  Sponsor (global 
or local)  
Inclisiran sodium 300 mg 
(equivalent to 284 mg 
inclisiran*) in 1.5 mL 
solution  Solution for injection  Subcutaneous injection  Solution for 
injection in pre-
filled syringe  Sponsor (global)  
Placebo  Solution for 
injection  Subcutaneous injection  Solution for 
injection in pre-
filled syringe  Sponsor (global)  
* Inclisiran is also referred to as KJX839  
6.1.2 Additional study treatments 
No other treatment beyond investigational drug and control drug are included in this trial. 
6.1.3 Treatment arms/group 
Part 1 (Year 1):  
Participants will be assigned at the baseline/randomization visit (Day 1) to one of the following 
two double-blind treatment groups in a 2:1 ratio: 
• Inclisiran sodium 300 mg s.c. 
• Corresponding placebo 
Each participant will receive one injection of blinded inclisiran or placebo on Day 1, a second 
injection of blinded inclisiran  or placebo on Day 90 and a subsequent injection of blinded 
inclisiran or placebo on Day 270 (“6 months dosing”). 
Part 2 (Year 2):  
Following a “Switch” Day (Day 360), all participants will receive the same active open -label 
inclisiran treatment:  
• Inclisiran sodium 300 mg s.c. 
Participants randomized to placebo in Part 1 will receive inclisiran sodium 300 mg s.c. starting 
on Day 360 (“Switch” Day 360). Participants randomized to inclisiran in Part 1 will receive placebo on Day 360. This dose of inclisiran/placebo on Day 360 will  remain blinded in order 
to maintain the blind for Part 1 of the study. 
All participants will receive subsequent doses of open- label inclisiran sodium 300 mg s.c. on 
Days 450 and 630. 
6.1.4 Treatment duration 
The expected duration of the participant’s involvement in the study will be approximately 748 
days, which includes a screening/run -in period (28 days) and subsequent treatment with study 
drug (1 year double -blind, placebo -controlled followed by 1 year open- label follow -up), with 
the EOS visit on Day 720 (Year 2). In addition, a safety follow -up call will be conducted [ADDRESS_683647] administration of study drug, whatever is longer. 
[COMPANY_001]  Confidential  Page 32 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Participants may be discontinued from treatment earlier due to safety reasons and/or at the 
discretion of the investigator or the participant’s parent(s)/legal representative(s) / participant (if applicable). They will continue to be followed up in the study unless informed consent is withdrawn ( Section  9.1.1 and Section  9.1.2).  
Participants who complete participation in this trial and continue to derive clinical benefit from the treatment based on the investigator’s evaluation may receive post- trial access (see 
Section  9.2). 
6.2 Other treatment(s)  
6.2.1 Concomitant therapy 
Concomitant lipid -lowering therapy  
Investigational and control drug will be given in addition to stable, individualized, optimal SoC for HoFH patients, which includes maximally tolerated dose of statin (investigator’s discretion) with or without other lipid -lowering therapy (e.g. ezetimibe) . Maximum tolerated dose of statin 
is defined as the maximum dose of statin that, at the investigator’s discretion, can be taken on a regular basis without AEs that would lead to a reduction in statin dose. Intolerance to statin must be documented as medic al history attributed to the statin in question in the source 
documentation and on an appropriate Electronic Case Report Form (eCRF). 
Participants are required to maintain their current lipid -lowering treatment unchanged for Part 
1 (Year 1) of the study, including the screening/run- in period (i.e. no medication or dose 
changes; see also Section  6.2.2). Lipid -lowering medications taken by [CONTACT_302000] [ADDRESS_683648] be recorded, including doses, 
on an appropriate eCRF. 
Participants on a documented regimen of LDL -apheresis will be allowed to continue their same 
regimen during the study, if needed. The apheresis schedule is not allowed to change during 
Part 1 (Year 1) of the study (including the screening/run -in period). T he apheresis schedule 
must also allow that an apheresis coincides with each study visit. Study drug is to be administered the same day, after completion of apheresis (the next scheduled apheresis should not occur within 72 hours after an administration of study drug). Blood samples for LDL -C (and 
other laboratory assessments of efficacy and safety) must be obtained immediately before the scheduled apheresis treatment at each applicable study visit (including screening and baseline (Day 1)). LDL -apheresis, w hich the participant receives from [ADDRESS_683649] all exclusion criteria.  
All other medications, procedures and significant non -drug therapi[INVESTIGATOR_014] (including physical 
therapy and blood transfusions) administered after the participant was enrolled into the study must also be recorded on appropriate eCRF pages. A new concomitant drug must be assessed against all prohibited medications prior to its initiation.  
[COMPANY_001]  Confidential  Page 33 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
If in doubt the investigator should contact [CONTACT_131342] a 
participant or allowing a new medication to be started. If the participant is already enrolled, contact [CONTACT_302001] s tudy medication. 
6.2.2 Prohibited medication 
Participants need to be on stable background lipid- lowering therapy for Part 1 (Year 1) of the 
study (including the screening/run- in period), i.e. the type and dose of lipid- lowering therapy 
must not be altered during this time. Use of the treatments displayed in Part A of Table  6-2 
below are therefore not allowed to be newly added at any time during Part 1 (Year 1) of the study, including the screening/run-in period. 
In addition, use of the treatments displayed in Part B of Table  6-2 below are not allowed at any 
time during the entire study duration. 
Table 6-2 Prohibited medication 
Medication Prohibition period  Action taken with study 
treatment  
PART A: Medications not allowed to be newly added during Part 1 (Year 1)  of the study  
Medications* prescribed to lower 
LDL-C (e.g., statins, ezetimibe, niacin, colesevelam, bile acid 
absorption inhibitors, LDL-apheresis)  
*For monoclonal  antibodies 
directed towards PCSK9, mipomersen and lomitapi[INVESTIGATOR_5328], see 
Part B  Part 1 (Year 1) of the study (including screening/run- in period)  None  
Any medication taken for the 
purpose of lipid -lowering, including 
over-the-counter or herbal 
therapi[INVESTIGATOR_526895] 1 (Year 1) of the study 
(including screening/run- in period)  None  
PART B: Regular prohibited medications  
Monoclonal antibodies directed 
towards PCSK9  Full Study Duration  Discontinue study treatment  
Mipomersen, lomitapi[INVESTIGATOR_526896]  
6.3 Participant numbering, treatment assignment, randomization  
6.3.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant throughout his/her entire participation in the trial. The Participant  No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential participant number suffixed to it, so that each participant’s participation is numbered uniquely across the entire database. Upon the part icipant’s parent(s)/legal representative(s) / participant 
(if applicable) signing the ICF, the participant is assigned to the next sequential Participant No. available.  
[COMPANY_001]  Confidential  Page 35 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Unblinding will occur in the case of participant emergencies and at the conclusion of the study. 
Unblinding of the CTT and other parties (as needed) will also occur after the Year [ADDRESS_683650] completed the Day 360 visit. 
Part 2 (Year 2)  
Due to the single -arm, open- label design, treatment in Part 2 of the study will be open to 
participants, investigator staff, persons performing the assessments, and the CTT.  
In order to  maintain the blind for Part 1 of the study, on the “switch” day (Day 360), participants 
randomized to placebo in Part 1 will receive blinded inclisiran, while participants randomized 
to inclisiran in Part 1 will receive blinded placebo.  
6.5 Dose escalation and dose modification  
Dose adjustments of study treatment are not permitted.  
6.5.1 Dose modifications  
Dosing with study treatment should be temporarily interrupted as follows:  
Part 1 (Year 1):  
• If from the Day 150 visit onwards a participant’s LDL -C is below 25 mg/dL (0.65 
mmol/L) at the last visit prior to the time of the next scheduled dose, the IRT will assign blinded placebo to be administered at the next scheduled dosing visit independent of which treatment group the participant was randomized to; i.e. if the participa nt was treated 
with inclisiran, study treatment will be interrupted in a blinded fashion via the IRT . 
Part 2 (Year 2):  
• If from the Day 450 visit onwards a participant’s LDL -C is below 25 mg/dL (0.65 
mmol/L) at the last visit prior to the time of the next scheduled dose, the investigator should withhold the dose at the next scheduled dosing visit. This will be flagged accordingly by [CONTACT_2237].  
• These dose interruptions must be recorded on an appropriate eCRF. 
Treatment discontinuation is mandatory for specific events listed in Section  9.1.1. 
6.5.2 Follow -up for toxicities 
[IP_ADDRESS] Follow up on potential drug- induced liver injury (DILI) cases 
Participants with transaminase increase combined with total bilirubin increase may be indicative of potentially severe DILI, and should be considered as clinically important events and assessed appropriately to establish the diagnosis. The required clinica l information, as 
detailed below, should be sought to obtain the medical diagnosis of the most likely cause of the observed laboratory abnormalities.  
The threshold for potential DILI may depend on the participant’s baseline AST/ALT and total 
bilirubin value; participants meeting any of the following criteria will require further follow -up 
as outlined below: 
[COMPANY_001]  Confidential  Page 36 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
• For participants with normal ALT and AST and total bilirubin value at baseline: AST or 
ALT  >3.0x ULN combined with total bilirubin >2.0x ULN 
• For participants with elevated AST or ALT or total bilirubin value at baseline: [AST or ALT >2.0x baseline] OR [AST or ALT >300 U/L] whichever occurs first combined with [total bilirubin >2.0x baseline AND >2.0x ULN] 
As DILI is essentially a diagnosis of exclusion, other causes of abnormal liver tests should be considered and their role clarified before DILI is assumed as the cause of liver injury.  
A detailed history, including relevant information such as review of ethanol consumption, concomitant medications, herbal remedies, supplement consumption, history of any pre -
existing liver conditions or risk factors, should be collected. 
Laboratory tests should include ALT, AST, total bilirubin, direct and indirect bilirubin, gamma -
glutamyl transferase (GGT), glutamate dehydrogenase (GLDH), prothrombin time 
(PT)/International Normalized Ratio (INR), alkaline phosphatase (ALP), albumin, and  creatine 
(phospho)kinase (C(P)K). 
Perform relevant examinations (Ultrasound or Magnetic resonance imaging (MRI), Endoscopic 
retrograde cholangiopancreatography (ERCP)) as appropriate, to rule out an extrahepatic cause of cholestasis. Cholestasis (is defined as an ALP elevation >2.0x ULN wi th R value < 2 in 
participants without bone metastasis, or elevation of the liver- specific ALP isoenzyme in 
participants with bone metastasis).  
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury. For children, 
there are caveats to calculating the R -ratio as normal levels of ALP are higher than in adults 
with standard ranges varying by [CONTACT_302003]. In clinical situations where it is suspected that ALP elevations are from an extra hepatic source, the GGT can be used if available. GGT 
may be less specific than ALP as a marker of cholestatic injury, since GGT can also be elevated by [CONTACT_6613]. It is more sensitive than ALP for detecting bile duct injury. 
Table  6-[ADDRESS_683651] (LFT) 
abnormalities.  
Table 6-3 Guidance on specific clinical and diagnostic assessments which can 
be performed to rule out possible alternative causes of observed LFT abnormalities 
Disease  Assessment  
Hepatitis A, B, C, E  • IgM anti -HAV; HBsAg, IgM & IgG anti -HBc, HBV DNA; anti -HCV, HCV 
RNA, IgM & IgG anti -HEV, HEV RNA  
CMV, HSV, EBV infection  • IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV 
Autoimmune hepatitis  • ANA & ASMA titers, total IgM, IgG, IgE, IgA  
Alcoholic hepatitis  • Ethanol history, GGT, MCV, CD -transferrin  
Nonalcoholic steatohepatitis  • Ultrasound or MRI  
[COMPANY_001]  Confidential  Page 38 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
6.6.2 Recommended treatment of adverse events 
Adverse events should be treated according to local practice and guidelines, and is at the 
discretion of the investigator and treating physician. 
For participants with injection site reaction, antihistamines, local or systemic steroids can be 
used at the investigator’s discretion depending on the severity of the reaction. 
Medication used to treat AEs must be recorded on appropriate eCRF page(s).  
6.6.[ADDRESS_683652] the participant’s 
next treatment regimen, and after discussion and agreement with the sponsor. Most often, study treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study participant who presents with an emergency condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then receive details of the investigational drug treatment for the specified participant and a fax or email confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the study team that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide: 
• protocol number 
• name 
• participant number  
In addition, oral and written information to the participant must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at any time.  
After an emergency un -blinding, study drug should be permanently discontinued. The 
participant will continue to be followed up in the study unless informed consent is withdrawn 
(Section  9.1.1 and Section  9.1.2).  
6.7 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational and control drugs section. 
A unique medication number is printed on the study medication label.  
Investigator staff will identify the study medication kits to administer to the participant by 
[CONTACT_105245](s). The study medication has a 2- part 
label (base plus tear -off label); immediately before using the medication kit, site personnel will 
detach the outer part of the label from the packaging and affix it to the source document. 
[COMPANY_001]  Confidential  Page 40 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Participants must be observed in the clinic for at least [ADDRESS_683653] injection on Day 1 and Day 
360 (i.e. first dosing of inclisiran) and for at least [ADDRESS_683654] a blood sample for tryptase within 30 minutes of the onset of anaphylaxis (or as soon as possible). 
All kits of study treatment assigned by [CONTACT_6607].  
All injections to the participant as well as study drug interruptions/discontinuations (i.e. no 
injection at a designated dosing visit) during the study must be recorded on an appropriate eCRF.  
7 Informed consent procedures  
Eligible participants may only be included in the study after the participant’s parent(s)/legal representative(s) or the participant (if applicable) provides (witnessed, where required by [CONTACT_6617]), Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent. 
In cases where the participant's parent(s)/legal representative(s) give consent, the participant 
must be informed about the study to the extent possible given his/her understanding. If the participant is capable of doing so, he/she should indicate assent by [CONTACT_90218] a separate assent form (as per local requirements). An informed consent must be obtained from the participant once he/she reaches the local legal age of adulthood during the study. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent and 
participant assent where applicable must be documented in the participant’s source documents. 
[COMPANY_001] will provide to investigators in separate documents proposed ICF(s) and age 
appropriate assent form(s) that comply with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and regulatory requirements and are c onsidered 
appropriate for this study. Any changes to the proposed consent/assent forms suggested by [CONTACT_6619]/IEC.  
Information about common side effects already known about the investigational drug can be found in the IB. This information will be included in the informed consent and should be discussed with the participant’s parent(s)/legal representative(s) and, to the extent possible, the participant during the study as needed. Any new information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notifica tion or an aggregate safety finding. New information 
might require an update to the informed consent/assent and then must be discussed with the participant’s parent(s)/legal representative(s) and, to the extent possible, the participant.  
Women of child bearing potential and her parent(s)/legal representative(s) must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the 
contraception requirements. 
[COMPANY_001]  Confidential  Page 42 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Table 8-1 Assessment Schedule 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  [CONTACT_302033] 1 
(Baseline 
& 1st Treatment)
 Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720  
(End of 
Treatment/ 
Study)3 Safety 
follow-up 
(last visit +30 days)
4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
Informed consent / 
assent (as 
applicable)  X             
Inclusion / Exclusion 
criteria  X             
Demography  X             
Pregnancy Test 
(serum)[ADDRESS_683655] 
(urine)5  S      S    S  
Relevant medical history/current 
medical conditions  X             
Medical history Statin intolerance (if 
applicable)  X             
Smoking & Alcohol 
history  X                         
Body weight / waist 
circumference  X X X X X X X X X X X X   
Body Height  X X     X   X     X   X   
Vital Signs6 X X X X X X X X X X X X   
Physical Exam 
(complete)  S           S         S   
[COMPANY_001]  Confidential  Page 43 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  [CONTACT_302033] 1 
(Baseline & 1st 
Treatment)
 Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720  
(End of 
Treatment/ 
Study)3 Safety 
follow-up (last visit 
+30 days)
4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
Physical Exam 
(abbreviated)    S S S S S   S S S S     
12-lead ECG  X           X         X   
Study drug 
administration7,8   X   X   X   X X   X     
IRT call  X X X X X X X X X X X X   
Prior/Concomitant 
lipid-lowering therapy  X X X X X X X X X X X X   
(Other) 
Prior/Concomitant 
Medications  X X X X X X X X X X X X   
Surgical/Medical 
Procedures  X X X X X X X X X X X X   
LDL- apheresis 
recording (if 
applicable)  X X X X X X X X X X X X   
Fasting LDL -C X X   X X X X X X X X X   
Fasting PCSK9    X   X X   X X   X   X   
Full fasting lipid / 
lipoprotein profile9   X     X   X X   X   X   
Anti-drug 
antibodies10   X     X   X     X   X   
Full chemistry11   X         X         X   
Limited chemistry11 X   X X X X   X X X X     
Hematology  X X X   X   X   X X   X   
Sexual hormones    X         X         X   
Urinalysis  X X X   X   X   X X   X   
[COMPANY_001]  Confidential  Page 44 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  [CONTACT_302033] 1 
(Baseline & 1st 
Treatment)
 Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720  
(End of 
Treatment/ 
Study)3 Safety 
follow-up (last visit 
+30 days)
4 
Days  -28 1 30 90 150 270 330 360 450 510 630 720 750 
AEs/SAEs  X X X X X X X X X X X X   
Injection site reaction 
assessment    X X X X X X X X X X X   
Neurological 
Examination    X         X         X   
Tanner staging / 
menarche    X     X   X     X   X   
Safety Follow up 
Call14                         S 
X Assessment to be recorded in the clinical database or received electronically from a vendor  
S Assessment to be recorded in the source documentation only  
1 Screening / run-in period  
2 Day 360 (“Switch Day”) is a shared visit, i.e. the end of Part 1 and the start of Part 2 of the study  
3 For participants who prematurely discontinue the study for any reason [e.g. if a participant’s parent(s)/legal representative(s) / a participant (if applicable) decide to 
prematurely and permanently discontinue the participant from study treatment and decline further follow -up visits] an EOS visit should also be scheduled as soon as 
possible.  
[ADDRESS_683656] administration of study drug, whatever is longer  
5 Only in females of child- bearing potential (prior to study treatment administration, if applicable)  
[ADDRESS_683657] injection; at all other visits, vital signs will be measured only once (prior to 
injection, if applicable).  
[ADDRESS_683658] injection for all other dosing visits.  

[COMPANY_001]  Confidential  Page 45 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Period  Screening1 Part 1 (Double -blind, placebo -controlled)  Part 2 (Open -label, single -arm)  Follow -up 
Visit Name  [CONTACT_302033] 1 
(Baseline & 1st 
Treatment)
 Day 30  Day 90  Day 150  Day 270  Day 330  Day 360 
("Switch 
Day")2 Day 450  Day 510  Day 630  Day 720  
(End of 
Treatment/ 
Study)3 Safety 
follow-up (last visit 
+30 days)
[ADDRESS_683659] a blood sample for tryptase within 30 minutes  of an onset of anaphylaxis (or as soon as 
possible).  
9 Apo B, Lp(a), non- HDL-C, total cholesterol, triglycerides, HDL-C, VLDL-C and Apo A1 in addition to the separately listed LDL- C (see Section 8.3 for details)  
10 ADA serum samples will be collected on Day 1 prior to injection and 4 hours after injection. At all other visits, one sample only will be collected.  
11 Diagnosis of diabetes based on fasting plasma glucose (FPG) should be verified by a repeat FPG within 6 weeks of the initial observation  
 
14 SAEs to be reported to [COMPANY_001] Safety (see Section 10.1.3  for details)  

[COMPANY_001]  Confidential  Page 46 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
8.1 Screening  
Screening activities ( Table  8-1) must be initiated only after the ICF (and assent if applicable) 
has been signed.  
It is not permissible to re -screen a participant if s/he fails the initial screening. In the case where 
a safety laboratory assessment at screening is outside of the range specified in the exclusion 
criteria, the assessment may be repeated once prior to randomization. If the repeat value remains outside of the specified ranges, the participant is not eligible for the study. 
8.1.1 Information to be collected on screening failures  
Participants for whom an ICF was signed and who are subsequently found to be ineligible prior 
to randomization will be considered a screen failure. The reason for screen failure should be recorded on an appropriate eCRF. The demographic information, informed consent, and inclusion/exclusion pages must also be completed for screen failure participants. If the screen 
failure participant experienced a SAE during the screening phase (see SAE section for reporting 
details) , SAE information must additionally be c ollected . If the participant fails to be 
randomized, the IRT must be notified within 2 days of the screen fail that the participant was not randomized. 
Participants who are randomized and fail to start treatment, e.g. participants randomized in 
error, will be considered an early terminator. The reason for early termination should be recorded on an appropriate eCRF. 
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.  
Participant demographic and baseline characteristic data to be collected on all participants include: age, sex, race, ethnicity, relevant medical history/current medical condition present before informed consent was signed (where possible, diagnoses and not symptoms will be recorded), concomitant lipid- lowering therapy, as well as relevant laboratory tests.  
Investigators will have the discretion to record abnormal test findings as medical history in an appropriate eCRF whenever, in their judgment, the test abnormality occurred prior to the informed consent signature. 
8.3 Efficacy  
The efficacy assessments are specified below, with the Assessment Schedule ( Table  8-1) 
detailing when each assessment is to be performed.  
All efficacy biomarkers will be analyzed at a Central laboratory(ies). Participants will be in a fasted state for all efficacy laboratory assessments.  At dosing visits, specimens for the analysis 
of efficacy biomarkers must be collected prior to study drug  administration. Details regarding 
the collection, processing, shippi[INVESTIGATOR_301976] a Laboratory Manual. The Laboratory Manual will also provide details about prioritization when blood volume is restrictive (Section  16.7 (Appendix 7)). 
[COMPANY_001]  Confidential  Page 48 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Laboratory tests and other assessments related to the secondary are 
in line with the expected efficacy of inclisiran.
 
8.4 Safety  
Safety assessments are specified below, with the Assessment Schedule ( Table  8-1) detailing 
when each assessment is to be performed.  
For details on AE collection and reporting, refer to the AE section. 
A complete physical examination will be performed at the screening visit, the Day 330 visit and 
at the Study Completion (EOS) visit. An abbreviated physical examination will be performed at other study visits detailed in Table  8-1. Details on what is included in the complete and 
abbreviated physical exams and the requirements to perform vital signs assessment and height / weight measurements are provided in Table  8-2. 
Table 8-2 Assessments & Specifications 
Assessment  Specification  
Physical examination  A complete physical examination  will include the examination of height, 
weight, general appearance, skin, neck (including thyroid), eyes, ears, nose, 
throat, lungs, heart, vital signs, abdomen, back, lymph nodes, extremities, 
vascular, and neurological. If indicated based on medical history and/or 
symptoms, rectal, external genitalia, breast, and pelvic exams will be 
performed.  
Tanner staging ( Section [IP_ADDRESS]) will additionally be performed at selected 
visits. 
A short physical examination  will include the examination of general 
appearance and vital signs as well as other examinations based on Investigator 
discretion. Height and weight will additionally be assessed as per the Schedule 
of Assessment.  
Information for all  physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are present 
prior to informed consent signature [CONTACT_526906]. Significant findings made after informed consent 
signature, which meet the definition of an AE, must be recorded as an AE.  
Vital signs  Vital signs include blood pressure and pulse measurements. After the participant has been sitting for five minutes, with back supported and both feet 
placed on the floor, systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) will be measured three times using an automated validated device, e.g. 
OMRON, with an appropriately sized cuff. The repeat sitting measurements will 
be made at 1 - 2 minute intervals and the mean of the three measurements will 
be used. In case the cuff sizes available are not  large enough for the 
participant's arm circumference, a sphygmomanometer with an appropriately 
sized cuff may be used.  
Clinically notable vital signs are defined in Section  16.2 (Appendix 2).  
Height and weight  Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in 
indoor clothing, but without shoes) will be measured. Height should be taken 
using a calibrated stadiometer.  
8.4.1 Laboratory evaluations  
Specimens will be obtained at the time points detailed in the Assessment Schedule ( Table  8-1). 
Details on what is included in hematology, chemistry, sexual hormones, and urinalysis 

[COMPANY_001]  Confidential  Page 49 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
laboratory evaluations are provided in Table  8-3. Efficacy laboratory assessments (e.g. LDL -
C) are described in Section  8.3. 
Central laboratory(ies) will be used for analysis of all specimens collected, with the exception 
of urine pregnancy tests, which will be done locally (using testing materials supplied by [CONTACT_2237]). Serum pregnancy tests at screening will be done by [CONTACT_2237]. Details on the collections, shipment of samples and reporting of results by [CONTACT_131356] a Laboratory Manual.  
Clinically notable laboratory findings are defined in Section  16.2 (Appendix 2).  
A table, which provides the maximum, allowable blood- draw volumes by [CONTACT_8497], can be found 
in Section  16.7 ( Appendix 7). The Laboratory Manual will also provide details about 
prioritization when blood volume is restrictive.  
Table 8-[ADDRESS_683660] Name  
[CONTACT_201101], hematocrit, red blood cell (RBC) count, mean cell hemoglobin (MCH), 
mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), 
white blood cell (WBC) count with differential (neutrophils, basophils, eosinophils, 
monocytes, lymphocytes ), platelet count  
Chemistry Full chemistry:  
AST, ALT, ALP, GGT, total bilirubin, direct and indirect bilirubin (if total bilirubin >2xULN), C(P)K, bicarbonate, uric acid, creatinine, blood urea nitrogen (BUN), eGFR*, 
sodium, potassium, calcium, phosphate, chloride, albumin, total protein, glucose (fasting)**, HbA
1C 
Limited chemistry:  
ONLY: AST, ALT, ALP, GGT, total bilirubin [fractionated bilirubin (if total bilirubin >2x 
ULN)], C(P)K, creatinine, eGFR*, glucose (fasting)**, HbA 1C 
Anti-drug 
antibodies  see Section [IP_ADDRESS]  
Sexual hormones  Gonadal hormones (estradiol for females and testosterone for males), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), cortisol and dehydroepi[INVESTIGATOR_2119] 
(DHEA)  
Urinalysis  Dipstick measurements for: specific gravity, pH, glucose, protein (total), ketones, 
bilirubin, urobilinogen, nitrite, hemoglobin (blood), leukocytes esterase  
If dipstick measurement results are positive (abnormal), microscopic examination will be 
performed  
Pregnancy test  Serum / Urine pregnancy test (see Section  8.4.3 ) 
Other  Tryptase (only as required***)  
* eGFR will be calculated using the Schwartz age-specific eGFR formula as follows:  
• For height in cm and serum creatinine (sCr) in mg/dL: eGFR (mL/min/1.73 m2) = 0.413 x (height/sCr)  
• For height in cm and sCr in μmol/L: eGFR (mL/min/1.732) = 36.5 x (height/sCr)  
** Diagnosis of diabetes based on FPG should be verified by a repeat FPG within 6 weeks of the initial 
observation  
*** Should a participant develop anaphylaxis on days when inclisiran is injected, the investigator will need to 
collect a blood sample for tr yptase within 30 minutes of the onset of anaphylaxis (or as soon as possible)  
[IP_ADDRESS] Anti-drug antibodies 
Serum samples for the analysis of formation of ADA will be collected at the time points detailed 
in the Assessment Schedule ( Table  8-1).  
[COMPANY_001]  Confidential  Page 50 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
On Day 1, ADA serum samples will be collected prior to injection and [ADDRESS_683661] be blinded to participants, investigator staff, persons performing the assessments, and the CTT. 
Instructions to be followed regarding sample collection, numbering, processing and shipment 
are outlined in a Laboratory Manual. 
8.4.2 Electrocardiogram (ECG)  
ECGs will be done with local ECG machines. ECGs must be recorded (after [ADDRESS_683662] in 
the supi[INVESTIGATOR_188597] a stable baseline). The preferred sequence of CV data collection during study visits is ECG collection first, followed by [CONTACT_18651], and blood sampling. The Fridericia QT correction formula (QTcF) should be used for clinical decisions.  
Single 12 lead ECGs are collected. The original ECGs on non- heat-sensitive paper and a copy 
(if original ECG done on heat sensitive paper), appropriately signed, must be collected and archived at the study site.  
For any ECGs with participant safety concerns, two additional ECGs must be performed to confirm the safety finding. A monitoring or review process should be in place for clinically significant ECG findings throughout the study and especially before adminis tration of study 
treatment.  
Any identifier details must be redacted e.g. participant initials, date of birth. 
Clinically significant abnormalities must be recorded on the eCRF as either Medical 
history/Current medical condition or AEs as appropriate.  
8.4.3 Pregnancy  
Females of child -bearing potential are defined as all females physiologically capable of 
becoming pregnant. This includes female adolescent participants who are menarchal or who become menarchal during the study. 
Serum/urine pregnancy tests will be performed for all female adolescents of child -bearing 
potential according to the Assessment Schedule ( Table  8-1). A positive urine pregnancy test 
should be confirmed with a serum pregnancy test. Additional pregnancy tests may be performed 
at the investigator’s discretion during the study and/or if requested by [CONTACT_5277]. 
Participants becoming pregnant must be discontinued from study drug. However, a participant 
may choose to remain in the study should she become pregnant, and be followed according to the protocol-defined study visits. 
All menarchal adolescents and their parent(s)/legal representative(s) should be informed about 
the potential risks of pregnancy and the need to prevent pregnancy during the study. 
It is important to be sensitive in introducing this issue, as understanding and comprehension of 
puberty, sexual activity, pregnancy and contraception is influenced by [CONTACT_302008], factors such as precocity, socio(educational) economic and familial back ground. These discussions 
with the participant and her parent(s)/legal representative(s) are therefore best performed by [CONTACT_526901] 51 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
requirements of the local regulatory authorities. These discussions should take into account the 
socio -economic, cultural factors and religious beliefs of the adolescent participant and her 
family. The investigator should also discuss the management of the  pregnancy test results with 
the participant and her parent(s)/legal representative(s). The privacy of the participant should be considered in accordance with the local law and ethics.  
8.4.4 Other safety evaluations  
[IP_ADDRESS] Pubertal development  
In addition to the assessment of height, weight and sexual hormones (see  Section  8.4.1), the 
following parameters will be monitored to evaluate pubertal development, at the time points detailed in the Schedule of Assessment ( Table  8-1):  
• Menarche (in females)  
• Tanner staging of sexual development (in males and females)  
Tanner staging will performed by a physician who (re -)familiarized him/herself with the Tanner 
stage assessment (in case needed) . The results (stages 1 -5 for the respective characteristics) will 
be recorded on an appropriate eCRF. Once a participant reaches Tanner stage 5, evaluations can be discontinued. For females, the date of menarche will also be recorded on an appropriate eCRF.  
[IP_ADDRESS] Neurological evaluation 
A full neurological evaluation will be performed as per the Schedule of Assessment ( Table  8-1). 
This should include assessment of motor function, sensory function, tone and reflexes and cerebellar function as detailed in  Section  16.5 (Appendix 5). 
Clinically significant abnormalities must be recorded on the eCRF as either Medical history/Current medical condition or AEs as appropriate.  
[IP_ADDRESS] Injection site reactions 
Injection site reactions (ISRs) should be monitored at each visit from the randomization (Day 1) visit onwards ( Table  8-1) and through additional contacts with the participant between visits 
as needed. ISRs including individual signs or symptoms at the injection site following study treatment administration should be recorded on an appropriate eCRF page. Every effort should be made to follow up with the participant until resolution of the ISR. 
[IP_ADDRESS] Anaphylactic reactions 
Potential anaphylactic reactions should be assessed by [CONTACT_76623] 
(see Section  16.6 ( Appendix 6)). If Samson criteria are positive, confirmation by [CONTACT_302010] 30 minutes of the onset of anaphylaxis (or as soon as possible).  
[IP_ADDRESS] Hyperglycemia- related events  
Laboratory results and newly added concomitant medications should be checked for potential hyperglycemia- related AEs.  
[COMPANY_001]  Confidential  Page 54 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
• Any other laboratory abnormalities that, in the judgment of the investigator, prevents the 
participant from continuing study treatment  
In addition, adolescent females who gain child -bearing potential during the study and are 
unwilling to comply with the requirements for contraception as outlined in Section  5.2 will be 
excluded from receiving further study drug. 
If discontinuation of study treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information.  
Study treatment may be restarted at the discretion of the investigator, if the reason for discontinuation has resolved. Every effort should be made to restart study treatment, if deemed appropriate by [CONTACT_093]. Study treatment is not allowed to be re -started following 
initiation of prohibited medication that requires study drug discontinuation ( Table  6-2).  
Participants who discontinue study treatment or for whom the participant’s parent(s)/legal representative(s) / participant (if applicable) decide that they do not to wish the participant to participate in the study further, should NOT be considered withdrawn from the study UNLESS informed consent was withdrawn (see Withdrawal of informed consent, Section  9.1.2). Where 
possible, they should return for the assessments indicated in the Assessment Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g. telephone, e -
mail, letter) should be made to contact [CONTACT_2299]’s parent(s)/legal representative(s) / participant / pre -designated contact [CONTACT_49425] -up section. This contact 
[CONTACT_526902] e according to the study visit schedule. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635], the participant’s parent(s)/legal representative(s) or with another pre -designated person. This telephone contact [CONTACT_302013].  
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits and/or via telephone/email contact: 
• New / concomitant treatments  
• AEs/SAEs  
Where possible, all clinic visit assessments should be performed according to Table  8-1. 
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study treatment. 
If discontinuation occurs because the treatment code has been broken, please refer to the 
Emergency breaking of treatment code section ( Section  6.6.3).  
9.1.2 Withdrawal of informed consent  
Participants’ parent(s)/legal representative(s) / participants (if applicable) may voluntarily withdraw consent for the participant to participate in the study for any reason at any time. Withdrawal of consent occurs only when a participant’s parent(s)/leg al representative(s) / 
participant (if applicable):  
• Does not want the participant to participate in the study anymore, 
[COMPANY_001]  Confidential  Page 55 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
and 
• Does not want any further visits or assessments  
and 
• Does not want any further study related contacts 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the decision to withdraw consent and record this 
information. 
Where consent to the use of personal and coded data is not required, participants’ parent(s)/legal 
representative(s) / participants (if applicable) therefore cannot withdraw consent. They still retain the right to object to the further use of personal data. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_6639] -up. 
All efforts should be made to complete the assessments prior to study discontinuation. A final evaluation at the time of the participant’s study discontinuation should be made as detailed in the Assessment Table ( Table  8-1). 
[COMPANY_001] will continue to retain and use all research results (data) that have already been collected for the study evaluation.  
Any adolescent’s (for whom the parent(s)/legal representative(s) provided informed consent) request to be withdrawn from the study should be respected and discussed in detail with the participant’s parent(s)/legal representative(s) and the local investigator before acting upon the request.   
9.1.[ADDRESS_683663] show "due diligence" by [CONTACT_6638] / participant’s parent(s) /legal representative(s), e.g. dates of telephone calls, registered letters, etc. A 
participant should not be considered as lost to follow -up until the end of each study part while 
due diligence has been completed. 
9.1.4 Early study termination by [CONTACT_30815]. 
Reasons for early termination:  
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study 
• Decision based on recommendations from applicable board(s) after review of safety and 
efficacy data 
• Discontinuation of study drug development 
[COMPANY_001]  Confidential  Page 56 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
In taking the decision to terminate, [COMPANY_001] will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible and treated as a prematurely withdrawn participant. The investigator may  be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
9.[ADDRESS_683664] medical occurrence (e.g. any unfavorable and unintended sign 
[including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after written informed consent was provided for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying AEs. 
[COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of AEs must be sought by [CONTACT_105]- directive questioning of the participant at each 
visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_6643], laboratory test findings, or other assessments. 
[COMPANY_001]  Confidential  Page 57 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Adverse events must be recorded in the AE eCRF under the signs, symptoms, or diagnosis 
associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade: 
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression of 
underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance  is that the symptoms of a lack of 
efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a single participant 
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported  
4. Whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. Action taken regarding with study treatment  
All AEs must be treated appropriately. Treatment may include one or more of the following: 
• Dose not changed 
• Drug interrupted/withdrawn  
6. Its outcome (i.e. not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal or unknown) 
Conditions that were already present at the time of informed consent should be recorded in the 
medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent (e.g. continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome. 
Information about ADRs for the investigational drug can be found in the IB. Abnormal laboratory values or test results constitute AEs only if they fulfill at least one of the 
following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from 
[COMPANY_001]  Confidential  Page 58 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_258382]. Alert ranges for laboratory abnormalities are included in 
Section  16.2  (Appendix 2). 
10.1.2 Serious adverse events 
An SAE is defined as any AE [appearance of (or worsening of any pre -existing)] undesirable 
sign(s), symptom(s) or medical conditions(s)) which meets any one of the following criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (HoFH) 
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_6534]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be considered as “medically significant”. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_6536] (please refer to the ICH -
E2D Guidelines). 
All new malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered SAEs irrespective if a clinical event has occurred (Table  10-1).  
[COMPANY_001]  Confidential  Page 59 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
10.1.[ADDRESS_683665] study visit (or  [ADDRESS_683666] 
administration of study drug, whatever is longer) must be reported to [COMPANY_001] Safety immediately, without undue delay, but under no circumstances later than within 24 hours of obtaining knowledge of the events (Note: If more stringent, local regulations regarding reporting timelines prevail). Detailed instructions regarding t he submission process and 
requirements are to be found in the investigator folder provided to each site. 
SAE reporting time frames are as follows:  
1. Screen failures: SAEs occurring after informed consent was provided until the time the 
participant is deemed a Screen Failure must be reported to [COMPANY_001].  
2. Randomized participants: SAEs collected between time informed consent was provided until [ADDRESS_683667] study visit (or [ADDRESS_683668] administration of study drug, whatever is longer) must be reported to [COMPANY_001]. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_6538], without undue delay, but under no circumstances later than within 24 hours of the investigator receiving the follow -up information (Note: If more stringent, local regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is suspected to be related to the study treatment, this event is considered a Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R). A Chief Medical Office and Patient  Safety (CMO & PS) 
Department associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001] may need to issue an Investigator Notification to inform all investigators involved in any study with the same s tudy treatment that this SAE has been 
reported. 
S[LOCATION_003]Rs will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with European Union (EU) Guidance 2011/C 172/[ADDRESS_683669] study visit (or  [ADDRESS_683670] administration of study drug, whatever is longer) should only be reported to [COMPANY_001] Safety if the investigator suspects a causal relationship to study treatment.  
10.1.4 Pregnancy reporting  
Pregnancies  
If a female trial participant becomes pregnant, the study treatment should be stopped, and the participant’s parent(s)/legal representative(s) / participant (if applicable) must be asked to read and sign a pregnancy consent form to allow the Study Doctor ask about her pregnancy. To ensure participant safety, each pregnancy occurring after signing the informed consent must be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
[COMPANY_001]  Confidential  Page 60 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
followed up until one year after the baby [CONTACT_302015], including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any 
birth defects, congenital abnormalities, or maternal and/or newborn complications.  
Pregnancy should be recorded and reported by [CONTACT_213767]&PS. Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational treatment of any pregnancy outcome. Any SAE experienced during pregnancy must be reported.  
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency (EMA) definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
an appropriate dosing eCRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type Document in Dosing 
eCRF (Yes/No)  Document in AE eCRF  Complete SAE form 
Unintentional study 
treatment error  Yes Only if associated with an 
AE Only if associated with an 
SAE 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.2 Additional Safety Monitoring  
10.2.1 Liver safety monitoring 
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of 
an investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
Please refer to Table  16-3 ( Section 16.3 ( Appendix 3)) for complete definitions of liver 
laboratory triggers.  
Once a participant is exposed to study treatment, every liver event defined in Table  16-3 should 
be followed up by [CONTACT_6648], as summarized 
[COMPANY_001]  Confidential  Page 61 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
below. Additional details on actions required in case of liver events are outlined in Table  16-4  
and Table  16-5 (Section 16.3 ( Appendix 3)). Requirements for follow -up of potential DILI 
cases is provided in Section  [IP_ADDRESS]. 
• Repeat liver chemistry tests (i.e. ALT, AST, total bilirubin, direct and indirect bilirubin, 
PT/INR, ALP , GGT , GLDH, albumin and C(P)K ) to confirm elevation.  
• These liver chemistry repeats will be performed using the central laboratory. If results will not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the participant. If a liver ev ent is subsequently 
reported, any local liver chemistry tests previously conducted that are associated with this event should have results recorded on an appropriate eCRF.  
• If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if deemed appropriate.  
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment section), if appropriate 
• Hospi[INVESTIGATOR_301978], if appropriate  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event should include  
• These investigations can include based on investigator’s discretion: serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
10.2.2 Renal safety monitoring 
To ensure participant safety and enhance reliability in determining the nephrotoxicity potential of an investigational drug, a standardized process for identification, monitoring and evaluation of renal events has to be followed. 
Every renal laboratory trigger or renal event as defined in Table  16-6 ( Section 16.4  
(Appendix 4)) should be followed up by [CONTACT_526903]  16-7 ( Section 16.4 (Appendix 4)).  
10.2.3 Other safety monitoring 
The frequency and severity of the AEs listed below will be monitored during the study. They 
will be reviewed by [CONTACT_302017].  
• ISRs (see also Section  [IP_ADDRESS]), hypersensitivity reactions and immune- mediated reactions  
• Hepatobiliary AEs and liver- related biochemical abnormalities (see also Section  [IP_ADDRESS]  
and Section  10.2.1) 
• Musculoskeletal AEs and muscle- related biochemical abnormalities (e.g. C(P)K) 
• Neurological or psychiatric AEs  
• New onset of diabetes or worsening of glycemic control in diabetics (see also Section  [IP_ADDRESS]) 
[COMPANY_001]  Confidential  Page 62 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
10.2.[ADDRESS_683671] injection of study drug and every 3 months thereafter until EOS, unless requested otherwise by [CONTACT_1363]. 
Specific details regarding composition, responsibilities, data monitoring and meeting 
frequency, and documentation of DMC reports, minutes, and recommendations will be described in a separate DMC charter that is established between the sponsor and the DMC.  
10.2.5 Steering Committee  
The Steering Committee (SC) will be established comprising representatives associated with the trial, but not being members of the DMC. [COMPANY_001] representatives from the Global Clinical Team can be present at the SC meetings.  
The SC will ensure transparent management of the study according to the protocol through recommending and approving modifications as circumstances require. The SC will review protocol amendments as appropriate. Together with the clinical team, the SC will also develop recommendations for publications of study results including authorship rules. The details of the role of the SC will be defined in the SC charter.  
[ADDRESS_683672] been built using fully validated secure web- enabled software that conforms to 21 Code of 
Federal Regulation (CFR) Part 11 requirements, Investigator site staff will not be given access to the Electronic Data Capture (EDC) system until they have been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_302018].  
The investigator/designee is responsible for assuring that the data entered into the eCRF is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate  
After final database lock, the investigator will receive copi[INVESTIGATOR_6540].  
All data should be recorded, handled and stored in a way that allows its accurate reporting, interpretation, and verification.  
[COMPANY_001]  Confidential  Page 63 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
11.2 Database management and quality control  
[COMPANY_001] personnel (or designated Contract Research Organization (CRO)) will review the data 
entered by [CONTACT_5375]. Electronic data queries stating the nature of the problem and requesting clarification will be crea ted for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
Concomitant treatments and prior medications entered into the database will be coded using the World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical con ditions and 
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed and all dosage changes will be tracked using an IRT. The system will be supplied by a vendor, who wil l also manage 
the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of [COMPANY_001].  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis. Any changes to the database after that time can only be made after 
written agreement by [CONTACT_109053].  
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and data capture requirements (i.e. eCRFs) with the investigators and their staff. During the study, [COMPANY_001] employs se veral methods of ensuring 
protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of participant records, the accuracy of data capture / data entry, the adherence to the protocol and to GCP, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, ECGs, and the results of any other t ests or assessments. All 
information on eCRFs must be traceable to these source documents in the participant’s file. The investigator must also keep the original signed ICF and the original signed assent form, if applicable (a signed copy is given to the p articipant’s parent(s)/legal representative(s)/ 
participant (if applicable)).  
[COMPANY_001]  Confidential  Page 64 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001] monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the eCRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
12 Data analysis and statistical methods 
Details of the statistical analysis and data reporting will be summarized in the  Statistical 
Analysis Plan (SAP) document finalized before data lock.  Any data analysis carried out 
independently by [CONTACT_30817].  
Efficacy and safety analyses of Part [ADDRESS_683673] completed the Day 360 visit or discontinued prior to the Day 360 visit. All available data from the clinical database will be included in the analysis. This analysis will be unblinded and 
reviewed by [CONTACT_302019]. 
12.1 Analysis sets  
The Full Analysis Set (FAS) comprises of all randomized participants with the exception of those mis -randomized participants who did not receive study drug. Mis -randomized participants 
are defined as not qualified for randomization and are inadvertently ra ndomized into the study. 
According to the intent to treat principle, participants will be analyzed according to the treatment they have been assigned to during the randomization procedure. The FAS will be used in analyses for the primary, secondary,  objectives.  
The Safety Set includes all participants who received at least one dose of study treatment. Participants will be analyzed according to the study treatment received. This will be the primary population for the safety analyses. 
12.[ADDRESS_683674] quartile wil l also be presented 
by [CONTACT_1570]. 
Relevant medical histories and current medical conditions at baseline will be 
summarized  separately  by [CONTACT_6657], by [CONTACT_1570]. Histories 
of statin intolerance and underlying genetic mutation will be summarized by [CONTACT_22058] t group. 
12.3 Treatments  
The Safety set will be used for the analyses below.  

[COMPANY_001]  Confidential  Page 65 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
The number of participants dosed at each dosing visit, number of study doses 
administered,  duration of exposure in days, and dose administered  will be summarized by 
[CONTACT_1570].  The number of study doses administered will be summarized by [CONTACT_12404] (Parts 1 and 2 combined). 
Lipid -modifying therapy use  at screening and the baseline/Randomization 
visit (Day 1)  will be summarized by [CONTACT_1570]. New or changed lipid- modifying therapy 
 after baseline will be summarized by [CONTACT_302021].  
Other concomitant medications and significant non -drug therapi[INVESTIGATOR_301979] 
(ATC) classification system, by [CONTACT_302022].  
12.4 Analysis of the primary endpoint(s)/estimand(s)  
12.4.[ADDRESS_683675] missing data imputed. Only data from the Day 330 visit 
time point and baseline data needed to evaluate change from baseline in LDL -C will be included 
in the primary analysis.  
12.4.5 Sensitivity analyses for primary endpoint/estimand 
No sensitivity analyses are planned.  
12.4.[ADDRESS_683676] subgroups.  
Details of any supplementary analyses that will be performed, including subgroups included in 
this analysis, will be specified in the SAP.  
12.4.7 Supportive analyses  
A linear mixed -effects model for repeated measures (MMRM) analysis will be used as a 
covariate -adjusted analysis of the difference in percent change from baseline to Day 330 in 
LDL -C. The MMRM will include fixed effects for treatment, visits, interaction b etween 

[COMPANY_001]  Confidential  Page 66 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
treatment and visits, and baseline LDL -C. The Restricted Maximum Likelihood (REML) 
estimation approach will be used with covariance structure set as "Unstructured". Two -sided 
95% confidence intervals for the difference between treatment groups will be prov ided. Full 
details of the supportive analysis will be provided in the SAP. 
12.5 Analysis of secondary endpoints/estimands  
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
Secondary efficacy endpoints include: 
• Time -adjusted percent change in LDL-C from baseline after Day 90 and up to Day 330 
(Year 1)  
• Percent change and absolute change in LDL- C from baseline to each assessment time up 
to Day 720 (Year 2) 
• Percent change and absolute change in Apo B from baseline to each assessment time up to 
Day 720 (Year 2) 
• Percent change and absolute change in Lp(a) from baseline to each assessment time up to Day 720 (Year 2) 
• Percent change and absolute change in non- HDL -C from baseline to each assessment time 
up to Day 720 (Year 2) 
• Percent change and absolute change in total cholesterol from baseline to each assessment time up to Day 720 (Year 2) 
• Percent change and absolute change in triglycerides from baseline to each assessment time up to Day 720 (Year 2) 
• Percent change and absolute change in HDL- C from baseline to each assessment time up 
to Day 720 (Year 2) 
• Percent change and absolute change in VLDL- C from baseline to each assessment time up 
to Day 720 (Year 2) 
• Percent change and absolute change in Apo A1 from baseline to each assessment time up to Day 720 (Year 2) 
• Percent change and absolute change in PCSK9  from baseline to each assessment time up 
to Day 720 (Year 2) 
Descriptive summaries by [CONTACT_2058].  
12.5.2 Safety endpoints 
For all safety analyses, the safety set will be used. All tables will be presented by [CONTACT_1570]. 
Safety summaries (tables, figures) include only treatment emergent events  (events started after 
the first dose of study medication or events present prior to start of double -blind treatment but 
increased in severity based on preferred term)  with the exception of baseline data which will 
also be summarized where appropriate (e.g. change from baseline summaries). In addition, a 
separate summary for deaths including on treatment and post treatment deaths will be provided. 
[COMPANY_001]  Confidential  Page 67 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
In particular, summary tables for adverse events (AEs) will summarize only treatment emergent 
AEs.  
Adverse events 
The number (and percentage) of  participants with treatment emergent adverse events in Part 1 
and Part 2 will be summarized in the following ways:  
• by [CONTACT_3148], primary system organ class and preferred term alphabetically.  
• by [CONTACT_3148], primary system organ class, preferred term alphabetically and maximum 
severity.  
• by [CONTACT_3148], primary system organ class and preferred term  alphabetically for treatment 
emergent AEs leading to study drug discontinuation. 
• by [CONTACT_3148], primary system organ class and preferred term  alphabetically for treatment 
emergent AEs related to study drug.  
The number (and percentage) of  participants with treatment emergent serious adverse events in 
Part 1 and Part 2  will be summarized in the following ways: 
• by [CONTACT_3148], primary system organ class and preferred term  alphabetically.  
• by [CONTACT_3148], primary system organ class and preferred term  alphabetically for  treatment 
emergent  serious AEs related to study drug. 
A separate summary  will be provided for adverse events leading to death. 
The number (and proportion) of  participants with adverse events of  special interest  will be 
summarized by [CONTACT_3148].  Categories of AEs used in this analysis will be specified in the SAP.  
A participant with multiple adverse events within a primary system organ class is only counted once towards the total of the primary system organ class.  
Vital signs  
All vital signs data will be listed by [CONTACT_1570],  participant, and visit/time and if ranges 
are available, abnormalities (and relevant orthostatic changes) will be flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
Baseline and change from baseline in height, weight, and BMI will be assessed using age- and sex-adjusted z-scores and summarized by [CONTACT_1570].  
Clinical laboratory evaluations 
Summary statistics will be provided by [CONTACT_6982]. Shift tables using the 
low, normal,  or high classification will be used to compare baseline to the worst on -treatment 
value by [CONTACT_302023] 1 and overall. The number (and percent age) of participants 
meeting clinically significant criteria will be provided by [CONTACT_302023] 1 and overall.  
[COMPANY_001]  Confidential  Page 70 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory 
authority, the investigator must inform [COMPANY_001] immediately that this request has been made.  
13.3 Publication of study protocol and results  
The protocol will be registered in a publicly accessible database such as clinicaltrials.gov and as required in European Union Drug Regulating Authorities Clinical Trials (EudraCT). In addition, after study completion (defined as last patient last visit) a nd finalization of the study 
report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority we bsites (e.g. Clinicaltrials.gov, EudraCT etc.). 
For details on the [COMPANY_001] publication policy including authorship criteria, please refer to the [COMPANY_001] publication policy training materials that were provided to you at the trial investigator meetings.  
13.[ADDRESS_683677] Operating Procedures (SOPs) as well as applicable global/local GCP regulations and ICH Guidelines. 
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
[ADDRESS_683678] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and health authorities, where required, it cannot be implemented. 
[COMPANY_001]  Confidential  Page 71 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
14.[ADDRESS_683679] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant included in this study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page 72 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
[ADDRESS_683680]  
Baigent C, Keech A, Kearney PM, et al (2005) Efficacy and safety of cholesterol -lowering 
treatment: prospective meta -analysis of data from 90,056 participants in 14 randomised trials 
of statins. Lancet; 366:1267-78. 
Barkas F, Liberopoulos EN, Kostapanos MS, et al (2015) Lipid target achievement among 
patients with very high and high cardiovascular risk in a lipid clinic. Angiology; 66(4):346-53. 
Bertolini S, Pi[INVESTIGATOR_20664] L, Rabacchi C, et al (2013) Spectrum of mutations and phenotypic 
expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis; 227: 342–348. 
Blom DJ, Harada -Shiba M, Rubba P, et al (2020) Efficacy and safety of Alirocumab in adults 
with Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. J Am Coll 
Cardiol; 76(2):131-42. 
Casula M, Tragni E, Catapano AL (2012) Adherence to lipid- lowering treatment: the patient 
perspective. Patient Prefer Adherence; 6:805 -14. 
Clinical Trials Facilitation and Coordination Group CTFG (2020). Recommendations related 
to contraception and pregnancy testing in clinical trials. Version 1.1. (Online ): 
https:www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2020_09_HMA_CTFG_Contraception_guidance_Version_1.1_updated.pdf (Accessed 15-Feb-2023).  
Cuchel M, Bruckert E, Ginsberg HN (2014) Homozygous familial hypercholesterolaemia: 
new insights and guidance for clinicians to improve detection and clinical management. A 
position paper from the Consensus Panel on Familial Hypercholesterolaemia of the Eu ropean 
Atherosclerosis Society. Eur Heart J; 35:2146-57. 
Davidson MH, Maki KC, Pearson TA, et al (2005) Results of the National Cholesterol 
Education (NCEP) Program Evaluation ProjecT Utilizing Novel E -Technology (NEPTUNE) 
II survey and implications for treatment under the recent NCEP Writing Group recommendatio ns. Am J Cardiol; 96:556-63. 
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute (2011) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics; 128 Supp 5:S213-S256. 
Ference BA, Ginsberg HN, Graham I, et al (2017) Low-density lipoproteins cause 
atherosclerotic cardiovascular disease. 1. Evidence from genetic, epi[INVESTIGATOR_50123], and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J; 38(32):2459-72. 
Fitzgerald K, White S, Borodovsky A, et al (2017) A Highly Durable RNAi Therapeutic 
Inhibitor of PCSK9. N Engl J Med; 376(1):41-51. 
[COMPANY_001]  Confidential  Page 73 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Giugliano RP, Pedersen TR, Park J- G, et al (2017) Clinical efficacy and safety of achieving 
very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a 
prespecified secondary analysis of the FOURIER trial. Lancet; 390:1962-71. 
Go AS, Mozaffarian D, Roger VL, et al (2014) Heart disease and stroke statistics -2014 
update: a report from the American Heart Association. Circulation; 129:e28 -e292. 
Grundy SM, Cleeman JI, Bairey Merz CN, et al (2004) Implications of recent clinical trials 
for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation; 110:227-39.  
Howie SRC (2011) Blood sample volumes in child health research: review of safe limits. Bull 
World Health Organ; 89:46-53. 
ICH Harmonized Guideline Addendum to ICH E 11 (2017) Clinical investigation of medicinal 
products in the pediatric population E11 (R1). (Internet) Available from: 
database.ich.org/sites/default/files/E11_R1_Addendum.pdf (Accessed 10 Jun 2020). 
Jameson K, Zhang Q, Zhao C, et al (2014) Total and low- density lipoprotein cholesterol in 
high- risk patients treated with atorvastatin monotherapy in the [LOCATION_008]: analysis of a 
primary -care database. Curr Med Res Opin; 30(4):655-65. 
Jones PH, Nair R, Thakker KM (2012) Prevalence of dyslipi[INVESTIGATOR_301980] 3 data sources: a retrospective analysis. J Am Heart Assoc.; 1(6):e001800. 
Khvorova A (2017) Oligonucleotide Therapeutics - A New Class of Cholesterol -Lowering 
Drugs. N Engl J Med; 376(1):4-7. 
Kolansky DM, Cuchel M, Clark BJ, et al (2008) Longitudinal evaluation and assessment of 
cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol; 102:1438-43. 
Lakoski SG, Lagace TA, Cohen JC, et al (2009) Genetic and metabolic determinants of 
plasma PCSK9 levels. J Clin Endocrinol Metab; 94:2537-43. 
Momper JD, Mulugeta Y, Green DJ, et al (2013) Adolescent dosing and labeling since the 
Food and Drug Administration Amendments Act of 2007. JAMA Pediatr; 167(10):926-32. 
Moorjani S, Roy M, Torres A, et al (1993) Mutations of low- density -lipoprotein-receptor 
gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous 
familial hypercholesterolaemia. Lancet; 341:1303 -6. 
Mousavi SA, Berge KE, and Leren TP (2009) The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med; 266(6):507- 19. 
Najam O, Ray KK (2015) Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiol Ther; 4(1):25-38. 
Nordestgaard BG, Chapman MJ, Humphries SE, et al (2013) Familial hypercholesterolaemia 
is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atheroscler osis 
Society. Eur Heart J; 34(45):3478- 90. 
[COMPANY_001]  Confidential  Page 74 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Raal FJ, Kallend D, Ray KK, et al (2020) Inclisiran for the Treatment of Heterozygous 
Familial Hypercholesterolemia. N Engl J Med; 382(16):1520-30. 
Ray KK, Stoekenbroek RM, Kallend D, et al (2019) Effect of 1 or 2 Doses of Inclisiran on 
Low-Density Lipoprotein Cholesterol Levels: One- Year Follow -up of the ORION-1 
Randomized Clinical Trial. JAMA Cardiol; 4(11):1067 -75. 
Ray KK, Wright RS, Kallend D, et al (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med; 382(16):1507-19. 
Sabatine MS, Giugliano RP, Keech AC, et al (2017) Evolocumab and Clinical Outcomes in 
Patients with Cardiovascular Disease. N Engl J Med; 376(18):1713-22. 
Sampson HA, Munoz-Furlong A, Bock SA, et al (2005) Symposium on the definition and 
management of anaphylaxis: summary report. J Allergy Clin Immunol; 115(3):584-91. 
Sampson HA, Munoz-Furlong A, Campbell RL, et al (2006) Second symposium on the 
definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol; 117(2):[ADDRESS_683681], Gidding SS, Hegele RA, et al (2016) Defining Severe Familial Hypercholesterolaemia and the Implications for Clinical Management: A Consensus Statement From the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lan cet Diabetes Endocrinol; 4:850-61. 
Schwartz GG, Steg PG, Szarek M, et al (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med; 379(22):2097-107. 
Stone NJ, Robinson JG, Lichtenstein AH, et al (2014) 2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation; 129 Supp 2:S1-S45. 
Thedrez A, Blom DJ, Ramin- Mangata S, et al (2018) Homozygous Familial 
Hype rcholesterolemia patients with identical mutations variably e xpress the LDLR (Low-
Density Lipoprotein R eceptor): Implications for the e fficacy of Evolocumab. Arterioscler 
Thromb Vasc Biol; 38(3):592-8. 
Varghese MJ (2014) Familial hypercholesterolemia: A review. Ann Pediatr Card; 7(2):107 -
17. WHO (2017) World Health Organization Cardiovascular diseases. (Internet) Available from: 
who.int/news- room/fact -sheets/detail/cardiovascular -diseases -(cvds) (Accessed 03 Jun 2020). 
Wiegman A, Gidding SS, Watts GF, et al (2015) Familial hypercholesterolaemia in children and adolescents: gaining decades of life by [CONTACT_302025]. Eur Heart J; 36:2425-37. 
Wilemon KA, Patel J, Aguilar-Salinas C, et al (2020) Reducing the Clinical and Public Health 
Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol; 5(2):217 -
29. 
[COMPANY_001]  Confidential  Page 75 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Youngblom E, Pariani M, and Knowles JW (2016) Familial Hypercholesterolemia. Initial 
posting: January 2, 2014; last update: December 8, 2016. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 -2016. Available from: ncbi.nlm.nih.gov/books/NBK174884/ (Accessed 27 Jan 
2020). 
[COMPANY_001]  Confidential  Page 76 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16 Appendices  
16.1 Appendix 1: Diagnostic criteria for HoFH  
Participants with a genetic diagnosis of HoFH by [CONTACT_526904] : 
• Documented homozygous or compound heterozygous mutations in both LDLR alleles 
• Note: Participants with known null (negative) mutations in both LDLR alleles, i.e. 
double null (negative), are not eligible (see Section 5.2 exclusion criteria)  
• Presence of homozygous or compound heterozygous mutations in A po B , PCSK9 , or low 
density lipoprotein receptor adaptor protein 1 (LDLRAP1) 
• Presence of double heteroz ygous mutations (i.e. mutations in different genes ) in the LDLR, 
Apo B, PCSK9, or LDLRAP1  alleles  (e.g. LDLR/PCSK9)  
[COMPANY_001]  Confidential  Page 77 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.2 Appendix 2: Clinically notable laboratory values and vital signs  
Criteria for clinically notable vital signs are defined in Table  16-1: 
Table 16-1 Criteria for clinically notable vital signs 
Age SBP [mmHg]  DBP [mmHg]  Heart Rate [beats min-1] 
12 years*  < 90, > 130  < 50, > 80  < 50, > 105  
>12 years  < 90, > 145  < 55, > 90  < 45, > 95  
* criteria for 6 -12 years  
Criteria for clinically notable laboratory values are defined in Table  16-2 : 
Table 16-2 Clinically notable laboratory abnormalities for selected tests 
Parameter  Alert Value  
Hematology  
RBC count  >50% increase, >30% decrease  
Hemoglobin  >50% increase, >30% decrease or any value <70 g/L 
(<7 g/dL)  
Hematocrit  >50% increase, >30% decrease  
WBC count  >50% increase, >50% decrease  
Platelet count  >75% increase, >50% decrease  
Clinical chemistry  
Albumin  <20 g/L (<2 g/dL)  
ALT >150% increase  
AST >150% increase  
Bilirubin (Total)  >100% increase  
BUN  >50% increase  
Calcium  >10% increase, >10% decrease  
C(P)K  >300% increase  
Creatinine  >50% increase  
Chloride  >10% increase, >10% decrease  
eGFR  >30% decrease  
Glucose  >50% increase, >50% decrease, or any value <3.3 
mmol/L (<60 mg/dL)  
Potassium  >20% increase, >20% decrease, or any value >5.3 
mmol/L (>5.3 mEq/L)  
Sodium  >5% increase, or any value >150 mmol/L (>150 
mEq/L)  
Uric acid  >50% increase  
[COMPANY_001]  Confidential  Page 78 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.3 Appendix 3: Liver event and laboratory trigger definitions & 
follow -up requirements  
Table 16-3 Liver event and laboratory trigger definitions 
  Definition/ threshold  
Liver laboratory triggers  
If ALT, AST and total bilirubin normal at baseline:  • ALT or AST > 5 × ULN 
• ALP > 2 × ULN (in the absence of known bone 
pathology)  
• Total bilirubin > 3 × ULN (in the absence of known 
Gilbert syndrome)  
• ALT or AST > 3 × ULN and INR > 1.5 
• Potential Hy’s Law cases (defined as ALT or AST 
> 3 × ULN and Total bilirubin > 2 × ULN [mainly 
conjugated fraction] without notable increase in ALP to > 2 × ULN)  
• Any clinical event of jaundice (or equivalent term)  
• ALT or AST > 3 × ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or 
vomiting, or rash with eosinophilia  
• Any adverse event potentially indicative of a liver 
toxicity*  
If ALT or AST abnormal at baseline:  • ALT or AST > 2x baseline or > 300 U/L (whichever 
occurs first)  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: upper limit of 
normal   
Table 16-[ADDRESS_683682] increase without bilirubin increase:    
 If normal at baseline:  
ALT or AST > [ADDRESS_683683]  Normal  
For participants 
with Gilbert’s syndrome: No 
change in 
baseline total 
bilirubin   None  • No change to study 
treatment  
• Measure ALT, AST, ALP, 
GGT, total bilirubin, direct 
and indirect bilirubin, 
PT/INR, albumin, C(P)K, 
and GLDH in 48-72 hours  
• Follow -up for symptoms  If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst) 
  If normal at baseline:  
ALT or AST > [ADDRESS_683684] for 
more than two weeks  Normal  
For participants 
with Gilbert’s 
syndrome: No 
change in 
baseline total bilirubin  None  • Interrupt study drug  
• Measure ALT, AST, ALP, 
GGT, total bilirubin, direct and indirect bilirubin, 
PT/INR, albumin, C(P)K, and GLDH in 48-72 hours  
• Follow -up for symptoms  
• Initiate close monitoring 
and workup for competing 
etiologies  If elevated at baseline:  
ALT or AST > 3 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst) for more than 
two weeks  
 If normal at baseline:  
ALT or AST > [ADDRESS_683685]  Normal  None  
[COMPANY_001]  Confidential  Page 79 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
  ALT or AST  Total bilirubin  Liver 
Symptoms  Action  
ALT or AST increase with bilirubin increase:  • Study drug can be restarted 
only if another etiology is 
identiﬁed and liver enzymes return to baseline
   If normal at baseline:  
ALT or AST > [ADDRESS_683686]  Total bilirubin > [ADDRESS_683687] (or INR > 
1.5) 
For participants 
with Gilbert’s syndrome: 
Doubling of direct 
bilirubin  None  
If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever occurs ﬁrst)
 
  If normal at baseline:  
ALT or AST > [ADDRESS_683688]  Normal or elevated  Severe fatigue, 
nausea, 
vomiting, right 
upper quadrant 
pain If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever 
occurs ﬁrst)  
Table 16-5 Follow up requirements for liver laboratory triggers  
Criteria  Actions required  Follow -up monitoring  
Total Bilirubin (isolated)  
>1.5 – 3.[ADDRESS_683689]  • Maintain treatment  
• Repeat LFTs within 48-72 
hours  Monitor LFTs weekly until 
resolutiona to ≤ Grade 1 or to 
baseline  
> 3 - 10 × ULN (in the absence of 
known Gilbert syndrome)  • Interrupt treatment  
• Repeat LFT within 48-72 hours  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and contributing 
factors (e.g. conmeds, medical 
history, lab) in the appropriate 
eCRF(s)  Monitor LFTs weekly until 
resolutiona to ≤ Grade 1 or to 
baseline (ALT, AST, total bilirubin, 
albumin, PT/INR, ALP and GGT)  
Test for hemolysis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> [ADDRESS_683690]  • Discontinue the study treatment immediately  
• Hospi[INVESTIGATOR_6548]  
• Establish causality  
• Record the AE and contributing 
factors(e.g. conmeds, medical history, lab) in the appropriate 
eCRF(s)  ALT, AST, total bilirubin, albumin, PT/INR, ALP and GGT until resolution
a (frequency at 
investigator discretion)  
Any AE potentially indicative of 
a liver toxicity  • Consider study treatment interruption or discontinuation  
• Hospi[INVESTIGATOR_6549]  
• Establish causality  
• Record the AE and contributing 
factors (e.g., conmeds, medical history, lab) in the appropriate 
eCRF(s)  Investigator discretion  
[COMPANY_001]  Confidential  Page 80 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
a Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 
months, (4) liver transplantation,  and (5) death  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include:  Serology tests, imaging and pathology assessments, hepatologist’s consultancy; 
obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease. 
[COMPANY_001]  Confidential  Page 81 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.4 Appendix 4: Specific Renal Alert Criteria and Actions and Event 
Follow -up 
Table 16-6 Specific Renal Alert Criteria and Actions 
Renal event  Actions  
Confirmed serum creatinine (sCr) increase 25 – 49% Consider causes and possible interventions  
Follow up within 2 -5 days  
Serum creatinine increase ≥ 50% + + OR if <18 
years old, eGFR ≤ 35 mL/min/1.73 m2 + Consider causes and possible interventions  
Repeat assessment within 24- 48h if possible  
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected  
Consider participant hospi[INVESTIGATOR_301981] ≥ 3+  
OR 
Protein-creatinine ratio (PCR) ≥ 1g/g Cr (or mg/mmol 
equivalent as converted by [CONTACT_526905])  Consider causes and possible interventions  
Assess serum albumin & serum total protein  
Repeat assessment to confirm  
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected  
New onset hematuria ≥ 3+ on urine dipstick  Repeat assessment to confirm  
Distinguish hemoglobinuria from hematuria  
Urine sediment microscopy  
Assess sCr 
Exclude infection, trauma, bleeding from the distal 
urinary tract/bladder, menstruation  
Consider bleeding disorder  
+ Corresponds to KDIGO (Kidney Disease: Improving Global Outcomes) criteria for Acute Kidney Injury  
 
Additional specialized assessments are available to assess renal function or renal pathology. 
(Note: In exceptional cases, when a nephrologist considers a renal biopsy, it is recommended 
to make slide specimen available for evaluation by [CONTACT_188664] -wide 
patterns of nephrotoxicity .) 
Whenever a renal event is identified, a detailed patient history and examination are indicated to 
identify and potentially eliminate risk factors that may have initiated or contributed to the event: 
• Blood pressure assessment (after [ADDRESS_683691], with an appropriate cuff size)  
• Signs and symptoms like fever, headache, shortness of breath, back or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema  
• Changes in blood pressure, body weight, fluid intake, voiding pattern, or urine output 
• Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic failure, contrast media or other known nephrotoxin administration, or other diseases or causes, e.g., dehydration due to delirium, tumor lysis  
[COMPANY_001]  Confidential  Page 82 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Table 16-[ADDRESS_683692] in appropriate eCRF(s):  
Urine dipstick and sediment microscopy evidence of drug- induced nephrotoxicity (DIN): crystals, red blood cells 
(dysmorphic/glomerular vs. non -dysmorphic/non-glomerular), white blood cells, tubular epi[INVESTIGATOR_526897], BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and uric acid  
Urine output  
Review and record possible contributing factors to the renal event (co-medications, other co-morbid conditions) 
and additional diagnostic procedures (MRI etc.) in the appropriate eCRF(s)  
Monitor participant regularly (frequency at investigator’s discretion) until – 
- Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or albumin-to -creatinine ratio (ACR) <300 
mg/g Cr)  
or 
- Event stabilization: sCr level with ±10% variability over last 6 months or protein-creatinine ratio stabilization at 
a new level with ±50% variability over last 6 months.  
- Analysis of urine markers in samples collected over the course of the DIN event  
[COMPANY_001]  Confidential  Page 83 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.5 Appendix 5: Recommended Neurological Examination 
MOTOR FUNCTION 
When assessing motor function, from a neurological perspective, the assessment should focus 
on arm and leg movement. You should consider the following: 
1. Muscle size  
2. Muscle tone  
3. Muscle strength  
4. Involuntary movement  
5. Posture, gait 
Symmetry is the most important consideration when identifying focal findings. Compare one 
side of the body to the other when performing your assessment. 
Assessment of a Conscious Patient  
Limb assessment of a conscious patient usually involves a grading of strength. 
Table 16-[ADDRESS_683693] gravity and resistance; normal muscle strength  
[ADDRESS_683694] gravity and a moderate amount of resistance; slight 
weakness  
[ADDRESS_683695] gravity only, moderate muscle weakness  
2 Full range of motion when gravity is eliminated, severe weakness  
1 A weak muscle contraction is palpated, but no movement is noted, very severe 
weakness  
0 Complete paralysis  
NB: In a conscious patient, the single best test to quickly identify motor weakness is the 
“drift test”. Have the patient hold their arms outward at [ADDRESS_683696] the patient close their eyes and hold the arms for a couple o f minutes. 
“Drifting” will occur if one side is weak.  
Lower Extremities  
Assess the patient in a supi[INVESTIGATOR_2547]. Ask him/her to separate both legs to test for hip abduction. Then ask the patient to bring the legs back together to test for hip adduction. Sit the patient on the side of the bed to assess knee flexion and extension. Ask the patient to flex and extend the knee. If able to do this, apply resistance as these movements are repeated. Test plantar and dorsiflexion by [CONTACT_302028]. Remember to compare the left side to the right side. 
Upper Extremities  
Assess ability to flex elbow (biceps) and straighten (triceps). Assess ability to raise shoulders and return to a resting position. Assess wrist flexion and extension. Test each function with resistance. For focused upper extremity assessment, assess each digit for flexion, extension and lateral movement.  
[COMPANY_001]  Confidential  Page 84 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Assessment of an Unconscious Patient  
Upper Extremities  
1. Observe the patient for spontaneous/involuntary movement. 
2. Apply painful stimuli to elicit a motor response (start with central pain; move to peripheral 
pain if no response occurs). 
3. Assess for paralysis of the limb by [CONTACT_302029]. If one 
limb is paralysed it will fall more rapi[INVESTIGATOR_301983].  
Lower Extremities  
1. Observe for spontaneous/involuntary movement. 
2. Apply painful stimuli to elicit a motor response. Begin with central pain. Nailbed or peripheral pain can be attempted if the patient doesn’t respond to central pain (caution needs to be used when interpreting peripheral pain as it may stimulate spi[INVESTIGATOR_526898]).  
3. To assess for paralysis of the one limb you can position the patient on their back and flex 
the knees so that both feet are flat on the bed. Release the knees simultaneously. If the leg 
falls to an extended position with the hip externally rotated, paralys is is present. The 
normal leg should stay in the flexed position for a few seconds and then gradually assume its previous position.  
SENSORY FUNCTION 
When assessing sensory function remember that there are three main pathways for sensation 
and they should be compared bilaterally: 
1. Pain and temperature sensation. 
2. Position sense (proprioception).  
3. Light touch. 
Pain can be assessed using a sterile pin. Light touch can be assessed with a cotton wisp. To test 
proprioception, grasp the patient's index finger from the middle joint and move it side to side and up and down. Have the patient identify the direction of movement. Repeat this using the great toe.  
Sensory Tests:  
A number of tests for lesions of the sensory cortex can be done. Examples include the following:  
• Stereognosis:  The ability to recognize an object by [CONTACT_265295]. Place a common object in the 
persons hand and ask them to identify the object. 
• Graphesthesis:  “Draw” a number in the palm of the person’s hand and ask them to 
identify the number.  
• Two -Point Discrimination: Simultaneously apply two pin pricks to the skin surface. 
Continually repeat the test while bringing the two pi[INVESTIGATOR_265261], until the individual can no longer identify two separate stimuli. The finger tips are the most sensitive location for recognizing two point differences while the upper arms, thighs and back are the least sensitive.  
[COMPANY_001]  Confidential  Page 85 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
• Extinction: Touch the same spot on both sides of the body at the same time (eg, the left 
and right forearms. Ask the individual to describe how many spots are being touched. Normally, both sides are felt; with sensory lesions the individual will sense only one.  
• Point Locations:  Touch the surface of the skin and remove the stimulus quickly. Ask the 
individual to touch the spot where the sensation was felt. Sensory lesions can impair accurate identification, even if they retain their sensation of light touch.  
TONE and REFLEXES  
Upper motor neuron problems (brain and spi[INVESTIGATOR_1831]) are associated with increased tone. Lower motor neuron problems are associated with decreased tone.  
Look at the muscles on each side of the body in pairs. Assess for symmetry of bulk. 
Evaluation of the stretch reflexes assesses the intactness of the spi[INVESTIGATOR_265262]. The limb should be relaxed while applying a short and snappy blow with a reflex hammer. Hold the hammer loosely in a relaxed manner, making a  wrist action. Allow the 
hammer to bounce. 
Table 16-9 Reflex responses 
Reflex responses  Description  
0 No response  
1+ Diminished, low normal  
2+ Average, normal  
3+ Brisker than normal  
4+ Very brisk, hyperactive  
Lower motor neuron disease is associated with 0 or 1+, upper motor neuron disease is associated with 3+ or 
4+. 
Biceps Reflex (C5 – C6):  
Support the forearm on the examiners forearm. Place your thumb on the bicep tendon (located in the front of the bend of the elbow; midline to the anticubital fossa). Tap on your thumb to stimulate a response.  
Triceps Reflex (C7 -C8):  
Have the individual bend their elbow while pointing their arm downward at 90 degrees. Support the upper arm so that the arm hangs loosely and “goes dead”. Tap on the triceps tendon located just above the elbow bend (funny bone). 
Brachioradialis Reflex (C5 -C6):  
Hold the person’s thumb so that the forearm relaxes. Strike the forearm about 2 -3 cm above the 
radial styloid process (located along the thumb side of the wrist, about 2-[ADDRESS_683697]). Normally, the forearm with flex and supi[INVESTIGATOR_265263].  
Quadriceps Reflex (Knee jerk) L2 – L4:  
Allow the lower legs to dangle freely. Place one hand on the quadriceps. Strike just below the knee cap. The lower leg normally will extend and the quadriceps will contract. 
[COMPANY_001]  Confidential  Page 86 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
If the patient is supi[INVESTIGATOR_050]: Stand on one side of the bed. Place the examiners forearm under the 
thigh closest to the examiner, lifting the leg up. Reach under the thigh and place the hand on the thigh of the opposite leg, just above the knee cap. Tap the kne e closest to the examiner, (the 
one that has been lifted up with the examiners forearm).  
Achilles Reflex (ankle jerks) L5 – S2:  
Flex the knee and externally rotate the hip. Dorsiflex the foot and strike the Achilles tendon of the heel. In conscious patients, kneeling on a chair can help to relax the foot. 
Heel Lift:  
While the patient is supi[INVESTIGATOR_050], bend the knee and support the leg under the thigh. Have the leg “go 
dead”. Briskly jerk the leg to lift the heel of the bed. Normally, the leg will remain relaxed and the heel will slide upward; increased tone will cause the heel and leg to stiffen and lift off the bed. 
Babinski Response:  
Dorsiflexion of the great toe with fanning of remaining toes is a positive Babinski response. 
This indicates upper motor neuron disease. It is normal in infants.  
CEREBELLAR FUNCTION  
The cerebellum is responsible for muscle coordination and balance on the same side. To test cerebellar function use the following tests:  
1. Finger to finger test: have the patient touch their index finger to your index finger (repeat several times).  
2. Finger to nose test: perform with eyes open and then eyes closed. 
3. Tandem walking: heel to toe on a straight line 
4. Romberg test: stand with feet together and arms at their sides. Have patient close his/ her eyes and maintain this position for [ADDRESS_683698] is “positive” or suggestive of cerebellum problems. 
Dizziness that occurs in response to position changes is usually blood pressure initiated. If the patient sways during a Romberg test, but stops when the eyes are opened, the problem is probably visual or CN VIII (vestibular).  
[COMPANY_001]  Confidential  Page 87 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.6 Appendix 6: Sampson Criteria for Diagnosing Anaphylaxis  
Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips- tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING:  
a. Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze -bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_10229] [PEF], hypoxemia) b. Reduced blood pressure or associated symptoms of end -organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence) 2. Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that 
patient (minutes to several hours):  
a. Involvement of the skin- mucosal tissue (eg, generalized hives, itch -flush, swollen lips -
tongue-uvula) 
b. Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze, bronchospasm, stridor, reduced PEF, 
hypoxemia) 
c. Reduced blood pressure or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence) 
d. Persistent gastrointestinal symptoms (eg, painful abdominal cramps, vomiting) 3. Reduced blood pressure after exposure to a known allergen for that patient (minutes to several 
hours): 
a. Infants and children: low systolic blood pressure (age specific) or >30% decrease in systolic 
blood pressure* 
b. Adults: SBP <90 mmHg or >30% decrease from that person’s Day 1 reading *Low SBP for children is age specific and defined as: <70 mmHg from age 1 month to 1 year; 
<70 mmHg + [2 x age] for age 1 to 10 years; <90 mmHg from age 11 to 17 years. 
Source: Sampson et al 2005 and Sampson et al 2006 
[COMPANY_001]  Confidential  Page 88 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
16.7 Appendix 7: Reference table blood volume by [CONTACT_302030] a maximum of 2.5% of the 
circulating blood volume per sampling session and to a maximum of 5% over a 4- week period 
(Table  16-10) (Howie  2011). Investigators may further limit the volume of blood withdrawn 
based on local institutional guidelines and if the clinical condition of the participant may be adversely affected by [CONTACT_302031]. Details of blood volume requir ement for biomarker and safety samples are provided in the laboratory manual.  
Table 16-10  Reference table – blood collection volumes by [CONTACT_302032] (kg)  Total b lood volume 
(TBV) of the participant 
(mL)1 Maximum allowable 
volume (mL) in one blood draw (2.5% of 
TBV)  Total maximum volume (mL) drawn in a 28-day 
period (5% of TBV)  
20 1600  40 80 
21 1680  42 84 
22 1760  44 88 
23 1840  46 92 
24 1920  48 96 
25 2000  50 100 
26 2080  52 104 
27 2160  54 108 
28 2240  56 112 
29 2320  58 116 
30 2400  60 120 
31 2480  62 124 
32 2560  64 128 
33 2640  66 132 
34 2720  68 136 
35 2800  70 140 
36 2880  72 144 
37 2960  74 148 
38 3040  76 152 
39 3120  78 156 
40 3200  80 160 
41 3280  82 164 
42 3360  84 168 
43 3440  86 172 
44 3520  88 176 
45 3600  90 180 
46 3680  92 184 
47 3760  94 188 
48 3840  96 192 
49 3920  98 196 
50 4000  100 200 
51 4080  102 204 
52 4160  104 208 

[COMPANY_001]  Confidential  Page 89 of 89 
Amended Protocol Version 02 (Clean )  Protocol No. CKJX839C12302  
 
Body Weight (kg)  Total b lood volume 
(TBV) of the participant 
(mL)1 Maximum allowable 
volume (mL) in one 
blood draw (2.5% of 
TBV)  Total maximum volume 
(mL) drawn in a 28-day 
period (5% of TBV)  
53 4240  106 212 
54 4320  108 216 
55 4400  110 220 
56 4480  112 224 
57 4560  114 228 
58 4640  116 232 
59 4720  118 236 
60 4800  120 240 
61 4880  122 244 
62 4960  124 248 
63 5040  126 252 
64 5120  128 256 
65 5200  130 260 
66 5280  132 264 
67 5360  134 268 
68 5440  136 272 
69 5520  138 276 
70 5600  140 280 
71 5680  142 284 
72 5760  144 288 
73 5840  146 292 
74 5920  148 296 
75 6000  150 300 
76 6080  152 304 
77 6160  154 308 
78 6240  156 312 
79 6320  158 316 
80 6400  160 320 
1: Assuming a TBV of 80 mL per kg  
For body weights not listed in the Table, use the following formulas to calculate 2.5% and 5% 
of total blood volume: 
• 2.5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 2 
• 5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 4 